ezogabine profile

Ezogabine is an anticonvulsant medication used to treat partial-onset seizures in adults. It is thought to work by enhancing the activity of a potassium channel in the brain, which helps to regulate the electrical activity of neurons. Ezogabine was first synthesized in the 1980s and was initially studied for its potential to treat a variety of neurological disorders. However, it was eventually approved specifically for the treatment of partial-onset seizures. Research on ezogabine continues to focus on its potential benefits and risks, as well as on its mechanism of action. It is also being investigated for its potential use in treating other neurological disorders, such as neuropathic pain.'

ezogabine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ezogabine : A substituted aniline that is benzene-1,2,4-triamine bearing ethoxycarbonyl and 4-fluorobenzyl substituents at positions N-1 and N-4 respectively. An anticonvulsant used to treat seizures associated with epilepsy in adults. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Products

ID Source	ID
PubMed CID	121892
CHEMBL ID	41355
CHEBI ID	68584
SCHEMBL ID	20835
MeSH ID	M0266905

Synonym
AC-6908
gtpl2601
150812-12-7
retigabine
n-(2-amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester
way-143841
n03ax21
add-230001
potiga
trobalt
ezogabine
aw21-360
gw-582892x
gke-841
ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate
ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate
d 20443
d 23129
n-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester
carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester
[2-amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-carbamate
d-23129
ZINC00016154
[2-amino-4-(4-fluoro-benzylamino)-phenyl]-carbamic acid ethyl ester
n-(2-amino-4-(4-fluorobenzylamino)-phenyl)carbamic acid ethylester
bdbm50143558
awd-21360
chebi:68584 ,
gw582892x
awd21-360
CHEMBL41355 ,
ethyl [2-amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]carbamate
ethyl n-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate
n-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamic acid ethyl ester
A809076
ethyl n-[2-azanyl-4-[(4-fluorophenyl)methylamino]phenyl]carbamate
ezogabine (usan)
retigabine (inn)
D09569
potiga (tn)
retigabine [inn]
potiva
12g01i6bbu ,
ezogabine [usan]
dea no. 2779
way 143841
gw 582892x
gki 841
hsdb 8171
unii-12g01i6bbu
S4733
HY-15471
CS-0990
retigabine,d2312, d-23129
BCP0726000089
FT-0601527
NCGC00346739-01
retigabine [who-dd]
ezogabine [vandf]
n-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester
retigabine [ema epar]
ezogabine [mi]
carbamic acid, (2-amino-4-(((4-fluoro-phenyl)methyl)amino)phenyl)-ethyl ester
retigabine [mart.]
ezogabine [orange book]
ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamate
AKOS015895311
RTG ,
DB04953
SCHEMBL20835
KE-0201 ,
PCOBBVZJEWWZFR-UHFFFAOYSA-N
2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzene
Q-101418
ethyl (2-amino-4-((4-fluorobenzyl)amino)phenyl)carbamate
DTXSID40164615
retigabine, analytical standard
ethyl n-(2-amino-4-{[(4-fluorophenyl)methyl]amino}phenyl)carbamate
FBX ,
retigabine, >=98% (hplc)
NCGC00346739-06
ethyl 2-amino-4-(4-fluorobenzylamino)phenylcarbamate
retigabin
BCP04194
retigabine (1.0 mg/ml in acetonitrile)
n-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid\|d-23129
EX-A2203
Q2146170
AMY18466
HMS3885L20
HMS3748I09
CCG-267503
NCGC00346739-05
ae3 - newer anti-epileptic drug mixtures 3

Excerpt	Reference	Relevance
"Ezogabine (EZG) is a potassium-channel opener that has been approved as adjunctive treatment for partial-onset seizures in adults with epilepsy. "	( The effect of ezogabine on the pharmacokinetics of an oral contraceptive agent. Buraglio, M; Crean, CS; Tompson, DJ, 2013)	2.19
"Ezogabine (retigabine) is a novel antiepileptic agent which primarily acts to stabilize neuronal potassium-gated ion channels. "	( Ezogabine: a novel antiepileptic as adjunctive therapy for partial onset seizures. Owen, RT, 2010)	3.25
"Ezogabine is a newly approved anticonvulsant for adjunctive therapy in partial-onset seizures in adults with a novel mechanism of action, activating low-threshold voltage-gated potassium channels. "	( Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review. Splinter, MY, 2012)	3.26
"Ezogabine (D-23129) is a recently approved antiepileptic drug approved by USFDA for adjunctive therapy of partial onset seizures."	( Ezogabine: development and role in the management of epileptic seizures. Kumar, M; Kumar, R; Verma, A, 2013)	2.55

Excerpt	Reference	Relevance
"Ezogabine has reported dose-dependent efficacy at doses of 600, 900, and 1200 mg/d."	( Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review. Splinter, MY, 2012)	2.54

Excerpt	Reference	Relevance
" Treatment discontinuations due to adverse events (AEs) were more likely with EZG (RTG) than with placebo (placebo, 8%; 600 mg, 17%, 900 mg, 26%)."	( Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Brodie, MJ; Elger, C; Gil-Nagel, A; Hall, S; Lerche, H; Mansbach, H; Nohria, V; Shin, P, 2010)	0.64
" Consequently, the adverse event (AE) profile of RTG/EZG includes a potential risk of effects on the urinary system."	( The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Brickel, N; DeRossett, S; Gandhi, P; Hammond, J; VanLandingham, K, 2012)	0.61
" In the network meta-analysis, RTG was not found to be different from the other AEDs for responder rate (maintenance period), seizure freedom (maintenance period and double-blind period), withdrawals due to adverse events, and incidences of ataxia, dizziness, fatigue and nausea."	( The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison. Cooper, J; Duffy, S; Glanville, J; Hugel, P; Lane, PW; Martyn-St James, M; McCool, R, 2012)	0.38
" Careful monitoring of drug interactions and adverse reactions is necessary."	( Ezogabine: an evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults. Welty, TE; Yamada, M, 2012)	1.82
" Treatments were generally tolerated, with no serious adverse events or discontinuations owing to adverse events."	( The effects of ethanol on the pharmacokinetics, pharmacodynamics, safety, and tolerability of ezogabine (retigabine). Crean, CS; Tompson, DJ, 2013)	0.61
"Central nervous system effects are predominant within the adverse event profiles of both ezogabine and perampanel."	( Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel. Burke, RA; Faulkner, MA, 2013)	0.82
" Discontinuation rates due to treatment-emergent adverse events (TEAEs) were numerically higher in the fast- (10/23) and medium- (7/22) titration groups than in the slow-titration group (3/23) but statistical significance was achieved only for the high-titration group compared with the low-titration group (p=0."	( Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures. Biton, V; Brodie, MJ; Derossett, SE; Gil-Nagel, A; Nohria, V, 2013)	0.63
" Safety assessments included adverse event (AE) monitoring, clinical laboratory evaluations, electrocardiograms, and physical and neurologic examinations."	( A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development. Biton, V; DeRossett, S; Nohria, V; Partiot, A; Porter, RJ; Rosenfeld, WE; Sachdeo, R; Tompson, D, 2014)	0.4
" The incidence of this significant adverse effect requires further investigation."	( Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. Bergman, R; Didkovsky, E; Feuerman, H; Garin Shkolnik, T; Hodak, E; Kaplan, I; Pavlovsky, L, 2014)	0.64
" Treatment-emergent adverse events occurred in 82% (CBZ/OXC), 76% (LTG), 73% (LEV), and 67% (VPA) of patients; most were of mild-to-moderate intensity."	( Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015)	0.73
" Safety assessments included monitoring treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)."	( Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events. Boll, MC; Brickel, N; Cooper, J; Daniluk, J; De'Ath, J; Hewett, K; Joshi, K; McDonald, S; Rayner, K; Tiamkao, S; Vorobyeva, O, 2020)	0.56
" In addition, comprehensive eye examination identified a new adverse reaction of acquired vitelliform maculopathy in a limited number of patients."	( Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events. Boll, MC; Brickel, N; Cooper, J; Daniluk, J; De'Ath, J; Hewett, K; Joshi, K; McDonald, S; Rayner, K; Tiamkao, S; Vorobyeva, O, 2020)	0.56

Excerpt	Reference	Relevance
" Pharmacokinetic parameters were compared between days and among dose groups."	( Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. Ferron, GM; Fruncillo, R; Getsy, J; Knebel, N; Paul, J; Richards, L; Troy, S, 2002)	0.31
" This study was performed to evaluate potential pharmacokinetic interactions between both AEDs."	( Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Borlak, J; Hermann, R; Knebel, NG; Locher, M; Niebch, G; Richards, L, 2003)	0.32
"RGB and LTG exhibit a modest pharmacokinetic interaction on each other."	( Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Borlak, J; Hermann, R; Knebel, NG; Locher, M; Niebch, G; Richards, L, 2003)	0.32
"To evaluate potential pharmacokinetic interactions between phenobarbitone and retigabine, a new antiepileptic drug."	( Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Ferron, GM; Parks, V; Patat, A; Rolan, P; Troy, SM, 2003)	0.32
"There was no pharmacokinetic interaction between retigabine and phenobarbitone in healthy subjects."	( Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Ferron, GM; Parks, V; Patat, A; Rolan, P; Troy, SM, 2003)	0.32
"The goal of this study was to examine the impact of coadministration of ethanol 1 g/kg on the safety and tolerability of EZG and the consequences of coadministration on pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers."	( The effects of ethanol on the pharmacokinetics, pharmacodynamics, safety, and tolerability of ezogabine (retigabine). Crean, CS; Tompson, DJ, 2013)	0.61
"This manuscript summarizes the pharmacokinetic and biopharmaceutical properties of retigabine collated from published and unpublished in vitro and clinical phase I-III studies in healthy volunteers or patients with partial-onset seizures."	( Clinical pharmacokinetics of retigabine/ezogabine. Crean, CS; Tompson, DJ, 2013)	0.66
" Thereafter, plasma concentrations decline in a mono-exponential manner, with a median half-life of 6-8 hours."	( Clinical pharmacokinetics of retigabine/ezogabine. Crean, CS; Tompson, DJ, 2013)	0.66
" Ethinyl estradiol Cmax was 21% lower with no change in AUC."	( The effect of ezogabine on the pharmacokinetics of an oral contraceptive agent. Buraglio, M; Crean, CS; Tompson, DJ, 2013)	0.75

Excerpt	Reference	Relevance
" The absolute oral bioavailability of retigabine is ~60%."	( Clinical pharmacokinetics of retigabine/ezogabine. Crean, CS; Tompson, DJ, 2013)	0.66
" It is well absorbed from the digestive system and undergoes metabolism via glucuronidation and acetylation."	( [Retigabine - a new antiepileptic drug with a different mechanism of action]. Pietrzak, B; Zwierzyńska, E, 2013)	0.39
" Oral or intraperitoneal administration of QO58-lysine, which has improved bioavailability and a half-life of approximately 3 h in plasma, can reverse inflammatory pain in rodent animal models."	( Activation of neuronal Kv7/KCNQ/M-channels by the opener QO58-lysine and its anti-nociceptive effects on inflammatory pain in rodents. Li, G; Ma, TY; Qi, JL; Song, Y; Teng, BC; Wang, K; Zhang, F; Zhang, HL, 2016)	0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" Plasma profiling and spectroscopic analysis (liquid chromatography with tandem mass spectrometry NMR) of two isolated urinary metabolites obtained after single oral dosing of 600 mg retigabine in healthy volunteers indicated that both acetylation and glucuronidation are major metabolic pathways of retigabine in humans."	( Metabolism of retigabine (D-23129), a novel anticonvulsant. Engel, J; Griesinger, C; Grunwald, C; Heinecke, K; Hempel, R; Kronbach, C; Kronbach, T; McNeilly, PJ; Schupke, H; Zimmermann, G, 1999)	0.3
" No dosage adjustment is likely to be necessary when retigabine and phenobarbitone are coadministered to patients."	( Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Ferron, GM; Parks, V; Patat, A; Rolan, P; Troy, SM, 2003)	0.32
" Blood samples were collected up to 60 h after dosing for plasma PK of RGB and AWD21-360."	( The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine. Borlak, J; Erb, K; Fuhr, U; Hermann, R; Maus, J; Munzel, U; Niebch, G, )	0.13
" The isobolographic analysis for parallel and nonparallel dose-response effects was used in the mouse maximal electroshock seizure (MES) model for evaluation of pharmacodynamic interaction."	( Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Czuczwar, SJ; Luszczki, JJ; Raszewski, G; Wu, JZ, 2009)	0.35
" Dose-response curves were obtained with increasing concentrations of the KCNQ((2-5)) selective positive modulator, retigabine or with the KCNQ((1-5)) negative modulator XE991."	( Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder. Rode, F; Rønn, LC; Sheykhzade, M; Svalø, J, 2010)	0.36
" Dosage adjustments are recommended in elderly patients and those with moderate and severe renal or moderate hepatic impairment."	( Clinical pharmacokinetics of retigabine/ezogabine. Crean, CS; Tompson, DJ, 2013)	0.66
" The final dosing regimen attained was maintained for an additional 14 days."	( A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development. Biton, V; DeRossett, S; Nohria, V; Partiot, A; Porter, RJ; Rosenfeld, WE; Sachdeo, R; Tompson, D, 2014)	0.4
" Likewise, information regarding the appropriate dosage of RTG with VPA, CBZ, PHT, or TPM was obtained, which permitted the subsequent pivotal trials to be performed appropriately."	( A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development. Biton, V; DeRossett, S; Nohria, V; Partiot, A; Porter, RJ; Rosenfeld, WE; Sachdeo, R; Tompson, D, 2014)	0.4
"To assess efficacy/tolerability of ezogabine (EZG)/retigabine (RTG) in combination with specified monotherapy antiepileptic drug (AED) treatments in adults with uncontrolled partial-onset seizures using a flexible dosing regimen."	( Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015)	1
"NCT01227902 was an open-label, uncontrolled study of flexibly dosed EZG/RTG."	( Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015)	0.73
"EZG/RTG was effective as adjunctive therapy to CBZ/OXC, LTG, LEV, and VPA, using a flexible dosing regimen, in adults with partial-onset seizures; safety and tolerability were consistent with that previously observed."	( Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015)	0.73
" Unlike other drugs, repeated dosing of retigabine was necessary to induce this effect."	( Profile of retigabine-induced neuronal apoptosis in the developing rat brain. Brown, L; Forcelli, PA; Gutherz, S; Kondratyev, A; Kulick, C; Soper, C, 2016)	0.43
"The aim of this review was to evaluate current literature for dosing recommendations for the use of antiepileptic medications in patients receiving renal replacement therapy (RRT)."	( Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016)	0.43
" Micromedex® DRUGDEX as well as package inserts were used to obtain known pharmacokinetic properties and dosage adjustment recommendations in RRT if known."	( Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016)	0.43
"Data regarding antiepileptic drug use in RRT are limited and mostly consist of case reports limiting our proposed dosing recommendations."	( Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016)	0.43
"Additional studies are necessary before specific dosing recommendations can be made for most antiepileptic drugs in critically ill patients receiving RRT, specifically with newer agents."	( Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016)	0.43
"Type I isobolographic analysis for nonparallel dose-response effects for the combination of retigabine with LCM (at the fixed-ratio of 1:1) in both the MES and chimney test in mice was performed."	( Beneficial Combination of Lacosamide with Retigabine in Experimental Animals: An Isobolographic Analysis. Adamczuk, P; Czuczwar, SJ; Florek-Luszczki, M; Kondrat-Wrobel, MW; Luszczki, JJ; Miziak, B; Wroblewska-Luczka, P; Zagaja, M; Zaluska, K, 2018)	0.48
"Linear regression analysis revealed that retigabine had its dose-response effect line nonparallel to that of LCM in both the MES and chimney tests."	( Beneficial Combination of Lacosamide with Retigabine in Experimental Animals: An Isobolographic Analysis. Adamczuk, P; Czuczwar, SJ; Florek-Luszczki, M; Kondrat-Wrobel, MW; Luszczki, JJ; Miziak, B; Wroblewska-Luczka, P; Zagaja, M; Zaluska, K, 2018)	0.48
" As part of a larger preclinical effort to gain a mechanistic understanding as to the origins of retinal pigment changes associated with RTG, we conducted a long-term repeat dosing study in rats."	( An Investigation into Retigabine (Ezogabine) Associated Dyspigmentation in Rat Eyes by MALDI Imaging Mass Spectrometry. Castellino, S; Groseclose, MR, 2019)	0.79

Product Category	Products
Vitamins & Supplements	1

Product	Brand	Category	Compounds Matched from Ingredients	Date Retrieved
Igennus Pharmepa Complete EPA - DHA - GLA Ultra Pure rTG Wild Fish Oil Lemon -- 1000 mg - 60 Softgels	Igennus	Vitamins & Supplements	Vitamin E, rTG, Vitamin E, linoleic acid	2024-11-29 10:47:42

Role	Description
anticonvulsant	A drug used to prevent seizures or reduce their severity.
potassium channel modulator	null
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
carbamate ester	Any ester of carbamic acid or its N-substituted derivatives.
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
substituted aniline
secondary amino compound	A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	21.3174	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	25.8870	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
G	Vesicular stomatitis virus	Potency	9.5221	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	18.9991	0.0010	8.3798	61.1304	AID1645840
Interferon beta	Homo sapiens (human)	Potency	9.5221	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	9.5221	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	9.5221	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	9.5221	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)	EC50 (µMol)	4.0217	0.0400	1.5208	4.3800	AID1557153; AID1604634; AID1604641; AID1874629; AID1874637; AID587711
Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)	EC50 (µMol)	2.6220	0.0400	1.3227	4.3800	AID1398549; AID1495580; AID1557153; AID1604634; AID1604640; AID1861507; AID1874629; AID1874637; AID313166; AID587711
UDP-glucuronosyltransferase 1A9	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 2B11	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 2B17	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
Potassium voltage-gated channel subfamily KQT member 2	Rattus norvegicus (Norway rat)	EC50 (µMol)	2.7867	2.0400	2.7867	4.1500	AID1586936; AID1894922; AID1894923
Potassium voltage-gated channel subfamily KQT member 3	Rattus norvegicus (Norway rat)	EC50 (µMol)	4.1500	4.1500	4.1500	4.1500	AID1894923
Sodium channel protein type 2 subunit alpha	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.1500	0.1500	0.1500	0.1500	AID313166
UDP-glucuronosyltransferase 2B4	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 2A1	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 2A2	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 2B7	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 1-6	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 1A1	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 1A4	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 1A3	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 1A5	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 2B10	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 2B15	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)	EC50 (µMol)	3.9400	1.6000	2.9700	5.9000	AID1586934; AID1604642
UDP-glucuronosyltransferase 2A3	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 2B28	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 1A7	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 1A10	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
UDP-glucuronosyltransferase 1A8	Homo sapiens (human)	EC50 (µMol)	3.9000	3.9000	3.9000	3.9000	AID1604641
Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)	EC50 (µMol)	2.1250	0.5000	1.7875	3.4500	AID1586935; AID1604643
Potassium voltage-gated channel subfamily KQT member 2	Mus musculus (house mouse)	EC50 (µMol)	1.3000	1.3000	1.3000	1.3000	AID246570; AID779736; AID94522
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)	Activity	0.3200	0.0400	0.2733	0.4600	AID1414250
Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)	EC2 (µMol)	0.3350	0.3300	1.0625	2.0000	AID1634031; AID1634032
Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)	Activity	0.3200	0.0400	0.2733	0.4600	AID1414250
Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)	EC2 (µMol)	0.3300	0.3300	1.1650	2.0000	AID1634031
UDP-glucuronosyltransferase 1A1	Homo sapiens (human)	Km	460.0000	4.4900	6.5133	9.0000	AID624630
UDP-glucuronosyltransferase 1A4	Homo sapiens (human)	Km	322.0000	7.0000	7.0000	7.0000	AID214939; AID624633
Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)	EC2 (µMol)	0.3400	0.3400	1.8067	3.5000	AID1634032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
protein targeting	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
protein import into nucleus	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
exocytosis	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
endocytosis	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
chemical synaptic transmission	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
sensory perception of sound	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
gene expression	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
response to auditory stimulus	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
response to organic cyclic compound	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
neuron remodeling	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
neuronal action potential	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
nerve development	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
psychomotor behavior	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
regulation of synaptic plasticity	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
neuron apoptotic process	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
mitochondrial depolarization	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
membrane hyperpolarization	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
cellular response to calcium ion	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
apoptosome assembly	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
excitatory chemical synaptic transmission	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
inhibitory chemical synaptic transmission	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
action potential initiation	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
regulation of action potential firing threshold	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
substantia propria of cornea development	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
chemical synaptic transmission	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
nervous system development	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
action potential	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
retinoic acid metabolic process	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
flavone metabolic process	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
flavonoid glucuronidation	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
liver development	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 2B11	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2B11	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 2B11	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2B11	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 2B17	Homo sapiens (human)
steroid metabolic process	UDP-glucuronosyltransferase 2B17	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2B17	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2B17	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2B4	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2B4	Homo sapiens (human)
sensory perception of chemical stimulus	UDP-glucuronosyltransferase 2A1	Homo sapiens (human)
sensory perception of smell	UDP-glucuronosyltransferase 2A1	Homo sapiens (human)
bile acid metabolic process	UDP-glucuronosyltransferase 2A1	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2A1	Homo sapiens (human)
bile acid metabolic process	UDP-glucuronosyltransferase 2A2	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2A2	Homo sapiens (human)
lipid metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
androgen metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
liver development	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
bilirubin conjugation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
acute-phase response	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to nutrient	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
steroid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
animal organ regeneration	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to lipopolysaccharide	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
retinoic acid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to starvation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
negative regulation of steroid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
flavone metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
flavonoid glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
biphenyl catabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to ethanol	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to glucocorticoid stimulus	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to estradiol stimulus	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
bilirubin conjugation	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
heme catabolic process	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
vitamin D3 metabolic process	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
bile acid secretion	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
retinoic acid metabolic process	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
flavonoid glucuronidation	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
vitamin D3 metabolic process	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A5	Homo sapiens (human)
lipid metabolic process	UDP-glucuronosyltransferase 2B10	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2B10	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2B10	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 2B15	Homo sapiens (human)
steroid metabolic process	UDP-glucuronosyltransferase 2B15	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2B15	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2B15	Homo sapiens (human)
potassium ion transport	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
sensory perception of sound	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
inner ear morphogenesis	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2A3	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2A3	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
steroid metabolic process	UDP-glucuronosyltransferase 2B28	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 2B28	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2B28	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2B28	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
coumarin metabolic process	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
retinoic acid metabolic process	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
flavone metabolic process	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
flavonoid glucuronidation	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
liver development	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
lipid metabolic process	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
flavone metabolic process	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
liver development	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
fatty acid metabolic process	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
steroid metabolic process	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
coumarin metabolic process	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
retinoic acid metabolic process	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
negative regulation of fatty acid metabolic process	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
negative regulation of steroid metabolic process	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
flavone metabolic process	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
flavonoid glucuronidation	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
liver development	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
calmodulin binding	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
calmodulin binding	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
ankyrin binding	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
protein binding	UDP-glucuronosyltransferase 2B11	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2B11	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 2B17	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2B17	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 2B4	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2B4	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2A1	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2A2	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
enzyme inhibitor activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
steroid binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A5	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A5	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A5	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A5	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2B10	Homo sapiens (human)
UDP-glycosyltransferase activity	UDP-glucuronosyltransferase 2B10	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 2B15	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2B15	Homo sapiens (human)
potassium channel activity	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2A3	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2B28	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
enzyme inhibitor activity	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
protein kinase C binding	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
protein kinase C binding	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
enzyme inhibitor activity	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
steroid binding	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
fatty acid binding	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
mitochondrion	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
node of Ranvier	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
axon initial segment	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
synapse	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily KQT member 3	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
node of Ranvier	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
axon initial segment	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
synapse	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
membrane	Potassium voltage-gated channel subfamily KQT member 2	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A9	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2B11	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2B17	Homo sapiens (human)
membrane	UDP-glucuronosyltransferase 2B17	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2B4	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2A1	Homo sapiens (human)
cellular_component	UDP-glucuronosyltransferase 2A2	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2A2	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
membrane	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
intracellular membrane-bounded organelle	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
plasma membrane	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
perinuclear region of cytoplasm	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum chaperone complex	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cytochrome complex	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A5	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A5	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2B10	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2B15	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
basal plasma membrane	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily KQT member 4	Homo sapiens (human)
membrane	UDP-glucuronosyltransferase 2A3	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nuclear outer membrane	UDP-glucuronosyltransferase 2B28	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 2B28	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2B28	Homo sapiens (human)
perinuclear region of cytoplasm	UDP-glucuronosyltransferase 2B28	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A7	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A10	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A8	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)
clathrin coat	Potassium voltage-gated channel subfamily KQT member 5	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1604636	Activation of human Kv7.2/Kv7.3 expressed in CHO cells assessed as delta V at 10 uM by whole cell patch clamp electrophysiology assay
AID1894922	Agonist activity at rat KCNQ2 channel expressed in CHO cells by patch clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1894930	Anticonvulsant activity in MES induced Kunming mouse model of seizure at 100 mg/kg, po	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1604625	Activation of human Kv7.2 expressed in CHO cells assessed as maximal steady-state increase in current amplitude at 10 uM measured within 10 secs at holding potential of -40 mV by whole cell patch clamp electrophysiology assay
AID1894901	Agonist activity at human KCNQ1 channel expressed in CHO cells assessed as shift of half voltage of maximal activation at 10 uM by patch clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1604660	Photostability of compound in pH 7.4 buffer assessed as metabolite with phenazinium-dimer formation incubated for 6 hrs under visible light irradiation by HPLC/MS/MS analysis
AID1634035	Selectivity index, ratio of EC2x for human Kv7.4/5 expressed in HEK293 cells to EC2x for EC2x for human Kv7.2/3 expressed in HEK293 cells
AID214939	Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4)	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
AID587711	Activation of KCNQ2/Q3 expressed in CHO cells by atomic absorption Rb'+ efflux assay	2011	European journal of medicinal chemistry, Mar, Volume: 46, Issue:3	Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.
AID1604630	Activation of human Kv7.2 expressed in CHO cells assessed as increase in maximal channel conductance at 0.03 uM in constant voltage pulses by whole cell patch clamp electrophysiology assay
AID1398554	Neurotoxicity in Sprague-Dawley rat at 25 mg/kg, ip measured after 30 mins by rotating-rod test	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy.
AID1894959	Anticonvulsant activity in C57BL/6 mouse 6 Hz seizure model at 32 mA measured after 1 hr	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID246570	Effect on outward potassium currents in whole-cell patch clamp assay of HEK 293 cells expressing cloned mouse KCNQ2 channel at -40 mV	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	(S,E)-N-[1-(3-heteroarylphenyl)ethyl]-3-(2-fluorophenyl)acrylamides: synthesis and KCNQ2 potassium channel opener activity.
AID1874646	Anticonvulsant activity in PTZ induced C57BL/6 mouse acute seizure model assessed as seizure score at 3 mg/kg, ip pretreated for 30 mins followed by PTZ injection and measured upto 30 mins by Liittjohann's scale analysis
AID1398553	Channel opening activity at KCNQ2 (unknown origin) expressed in CHO cells assessed as change in half activation potential at 10 uM by electrophysiological patch-clamp test	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy.
AID1604643	Activation of human Kv7.5 expressed in CHO cells assessed as increase in channel current amplitude by whole cell patch clamp electrophysiology assay
AID1604649	Photostability of compound in pH 7.4 buffer assessed as compound degradation at 100 ug/ml incubated for 2 hrs under natural solar light-irradiation by HPLC analysis relative to control
AID1634036	Half life in human liver microsomes
AID1495580	Activation of KCNQ2 (unknown origin) expressed in CHO cells at 10 uM after 10 mins by atomic absorption spectrophotometry-based Rb+ flow assay	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents.
AID94521	Efficacy for mKCNQ2 expressed in HEK293 cells relative to reference compound	2004	Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8	(S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons.
AID1894954	Ratio of TC50 for Kunming mouse to EC50 for anticonvulsant activity in Kunming mouse	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1861509	Agonist activity at Kv7.2 W236L mutant (unknown origin) assessed as shifting of voltage dependent activation to more negative potentials at 5 uM by SyncroPatch assay	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Development of an automated screen for Kv7.2 potassium channels and discovery of a new agonist chemotype.
AID1604658	Photostability of compound in pH 7.4 buffer assessed as retention time of metabolite incubated for 6 hrs under visible light irradiation by HPLC/MS analysis
AID1874632	Metabolic stability in human liver S9 fraction assessed as phase 2 metabolism by UHPLC-MS/MS analysis
AID313159	Analgesic activity in formalin-induced pain hypersensitivity in po dosed rat	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Kv7 (KCNQ) channel modulators and neuropathic pain.
AID1414250	Activation of human wild type Kv7.2/7.3 expressed in CHO cells assessed as 86Rb efflux at 0.001 to 100 uM after 10 mins by microbeta liquid scintillation counting analysis	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	Novel K
AID1293292	Antiepileptic activity in po dosed KM mouse assessed as protection against maximal electroshock-induced seizures administered 30 mins prior to electrical stimulation	2016	Journal of natural products, Jan-22, Volume: 79, Issue:1	Identification and Evaluation of Antiepileptic Activity of C21 Steroidal Glycosides from the Roots of Cynanchum wilfordii.
AID1604645	Photostability of compound in pH 7.4 buffer assessed as compound degradation at 100 ug/ml incubated for 6 hrs under artificial daylight D65 lamp-irradiation by HPLC analysis relative to control
AID1604657	Activation of human Kv7.1 expressed in CHO cells assessed as channel current amplitude at 10 uM measured at holding potential of +20 mV and -40 mV by whole cell patch clamp electrophysiology assay
AID1414251	Activation of human Kv7.2 W236L mutant/Kv7.3 W265L mutant expressed in CHO cells assessed as 86Rb efflux at 0.001 to 100 uM after 10 mins by microbeta liquid scintillation counting analysis	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	Novel K
AID1495581	Activation of KCNQ2 (unknown origin) expressed in CHO cells assessed as conductivity (I/I0) at 10 uM by electrophysiological patch-clamp test	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents.
AID1894940	Ratio of drug concentration in brain to plasma of MES induced Kunming mouse model of seizure	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1604654	Activation of human Kv7.2 expressed in CHO cells assessed as current amplitude at 10 uM measured after 10 secs upon drug wash-out at holding potential of -40 mV by whole cell patch clamp electrophysiology assay
AID1604633	Activation of ICA-insensitive human Kv7.2 F168L mutant expressed in CHO cells assessed as increase in channel current amplitude at 10 uM measured at holding potential of -40 mV by whole cell patch clamp electrophysiology assay
AID1874657	Drug concentration in C57BL/6 mouse plasma at 1 mg/kg, ip measured after 60 mins by UHPLC-MS/MS analysis
AID1894955	Anticonvulsant activity in Kunming mouse assessed as reduction in MES-induced seizure after 1 hr	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1398551	Channel opening activity at KCNQ2 (unknown origin) expressed in CHO cells assessed as conductivity (I/I0 ratio) at 10 uM by electrophysiological patch-clamp test	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy.
AID1874628	Activation of Kv7.2/Kv7.3 channel (unknown origin) expressed in CHO cells assessed as slope of fluorescent signal at 10 uM by FluxOR fluorescent dye based assay
AID1604623	Activation of human Kv7.2 expressed in CHO cells assessed as increase in current amplitude at 10 uM measured at holding potential of -40 mV by whole cell patch clamp electrophysiology assay relative to control
AID1894927	Anticonvulsant activity in pentylenetetrazol induced Kunming mouse model of seizure at 30 mg/kg, po after 1 hr	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1894943	Anticonvulsant activity in Kunming mouse plasma assessed as plasma EC50 level by rotarod test	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1604641	Activation of human Kv7.3 expressed in CHO cells assessed as increase in channel current amplitude by whole cell patch clamp electrophysiology assay
AID1604659	Photostability of compound in pH 7.4 buffer assessed as formation of 4-fluorobenzaldehyde incubated for 6 hrs under visible light irradiation by GCMS analysis
AID1586936	Agonist activity at rat KCNQ2 expressed in CHOK1 cells by whole cell patch clamp assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity.
AID1874656	Drug concentration in C57BL/6 mouse brain at 1 mg/kg, ip measured after 60 mins by UHPLC-MS/MS analysis
AID1861507	Agonist activity at Kv7.2 (unknown origin) assessed as shifting of voltage dependent activation to more negative potentials by SyncroPatch assay	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Development of an automated screen for Kv7.2 potassium channels and discovery of a new agonist chemotype.
AID1894929	Anticonvulsant activity in MES induced Kunming mouse model of seizure at 60 mg/kg, po	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1894923	Agonist activity at rat KCNQ2/3 channel expressed in CHO cells by patch clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID94518	Increased outward current at -40 mV mediated by mouse KCNQ2 channel expressed in Xenopus laevis oocytes at 20 uM	2004	Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7	The synthesis and structure-activity relationships of 3-amino-4-benzylquinolin-2-ones; discovery of novel KCNQ2 channel openers.
AID1894917	Agonist activity at human KCNQ4 channel expressed in CHO cells assessed as amplitude change of outward current at 10 uM by patch clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID313170	Analgesic activity in formalin-induced pain hypersensitivity in ip dosed rat	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Kv7 (KCNQ) channel modulators and neuropathic pain.
AID1477024	Antagonist activity at NMDA receptor in human IMR90-c4 cells assessed as decrease in NMDA-mediated reduction in cell viability at 0.1 to 10 uM by PrestoBlue assay	2017	Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23	Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID313168	Therapeutic index, ratio of ED50 in rotor rod test in rat to ED50 in rat kindling model of epileptic seizures	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Kv7 (KCNQ) channel modulators and neuropathic pain.
AID1604624	Activation of human Kv7.2 expressed in CHO cells assessed as increase in current amplitude with fast ON kinetics measured at holding potential of -40 mV by whole cell patch clamp electrophysiology assay
AID94522	Whole-cell patch-clamp on recombinant mouse KCNQ2 channels expressed in HEK 293 cells at -40 mV	2004	Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8	(S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons.
AID1604652	Drug metabolism in human liver S9 fractions assessed as assessed as UGT-mediated phase 2 metabolism at 1 mM preincubated for 5 mins followed by NADPH addition and measured after 60 mins by RP-UHPLC-DAD analysis relative to control
AID1249435	Intrinsic clearance in human liver microsomes measured over 1 hr in presence of NADPH regenerating system	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Discovery of a novel Kv7 channel opener as a treatment for epilepsy.
AID1894944	Ratio of drug concentration in Kunming mouse brain to plasma by rotarod test	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1634032	Agonist activity at human Kv7.3/Kv7.5 expressed in HEK293 cells assessed as drug concentration that doubles the conductance at voltage leading to 15% channel activation at holding potential of at -80 mV by whole cell patch clamp electrophysiology assay
AID1894961	Toxicity in C57BL/6 mouse assessed as sedative effect at 80 mg/kg	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1874638	Activation of Kv7.2/Kv7.3 channel (unknown origin) expressed in CHO cells assessed as fold change in maximum current density measured after 24 hrs by whole cell patch clamp based electrophysiological method relative to control
AID1874645	Anticonvulsant activity in PTZ induced C57BL/6 mouse acute seizure model assessed as seizure score at 1 mg/kg, ip pretreated for 30 mins followed by PTZ injection and measured upto 30 mins by Liittjohann's scale analysis
AID1894953	Drug concentration in Kunming mouse plasma at 300 mg/kg	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1894947	Neurotoxicity in po dosed Kunming mouse assessed as motor impairment after 1 hr by rotarod test	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1604632	Activation of human Kv7.2 W236L mutant expressed in CHO cells assessed as channel current amplitude at 10 uM measured at holding potential of -40 mV by whole cell patch clamp electrophysiology assay
AID1894952	Drug concentration in Kunming mouse brain at 300 mg/kg	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1894831	Agonist activity at rat Kv7.2 channel expressed in CHO cells assessed as amplitude change of outward current at 10 uM by whole cell patch clamp based electrophysiological method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID313165	Activity at Kv.7 channel expressed in cloned CHO cells by patch clamp method	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Kv7 (KCNQ) channel modulators and neuropathic pain.
AID1604648	Photostability of compound in pH 7.4 buffer assessed as formation of 4-fluorobenzaldehyde incubated for 6 hrs under visible light irradiation by HPLC analysis
AID1477012	Neuroprotective activity against etoposide-induced apoptosis in rat PC12 cells assessed as cell viability at 3 uM pretreated for 4 hrs followed by etoposide challenge measured after 48 hrs by PrestoBlue assay (Rvb = 52.13 +/- 1.13%)	2017	Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23	Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1894933	Anticonvulsant activity in po dosed MES induced Kunming mouse model of seizure	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1894920	Agonist activity at human KCNQ5 channel expressed in CHO cells assessed as shift of half voltage of maximal activation at 10 uM by patch clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1874629	Activation of Kv7.2/Kv7.3 channel (unknown origin) expressed in CHO cells assessed as slope of fluorescent signal by FluxOR fluorescent dye based assay
AID1604631	Activation of human Kv7.2 expressed in CHO cells assessed as half-activation voltage at 0.03 uM in constant voltage pulse by whole cell patch clamp electrophysiology assay (Rvb = -38.2 +/- 2 mV)
AID313166	Activity at Kv 7.2 channel expressed in cloned CHO cells by [86Rb] efflux assay	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Kv7 (KCNQ) channel modulators and neuropathic pain.
AID1604622	Activation of human Kv7.2 expressed in CHO cells assessed as increase in current amplitude at 10 uM measured at holding potential of 0 mV by whole cell patch clamp electrophysiology assay relative to control
AID1586942	Effect on voltage-dependent activation of human KCNQ4 expressed in CHOK1 cells assessed as negative shift in current activation curve at 10 uM by whole cell patch clamp assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity.
AID1874634	Activation of Kv7.2/Kv7.3 channel (unknown origin) expressed in CHO cells assessed as leftward shift change in half activation potential at 1 uM measured after 24 hrs by whole cell patch clamp based electrophysiological method
AID1894830	Agonist activity at rat Kv7.2 channel expressed in CHO cells assessed as shift of half voltage of maximal activation at 10 uM by whole cell patch clamp based electrophysiological method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID779735	Induction of mouse KCNQ2 expressed in HEK293 cells at -40 mV holding potential by whole-cell patch clamp assay relative to (+/-)-N-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(2-chlorophenyl)acrylamide	2013	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22	Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl)ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic pain.
AID1894913	Agonist activity at rat KCNQ2/3 channel expressed in CHO cells assessed as amplitude change of outward current at 10 uM by patch clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1249437	Efflux ratio of permeability from apical to basolateral over basolateral to apical side in MDCK cells transfected with MDR1	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Discovery of a novel Kv7 channel opener as a treatment for epilepsy.
AID1894903	Agonist activity at human KCNQ1 channel expressed in CHO cells assessed as amplitude change of outward current at 10 uM by patch clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1894938	Anticonvulsant activity in MES induced Kunming mouse model of seizure assessed as EC50 in brain	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1398549	Channel opening activity at KCNQ2 (unknown origin) expressed in CHO cells after 10 mins by atomic absorption spectrophotometry-based Rb+ flow assay	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy.
AID313169	Therapeutic index, ratio of ED50 in rotor rod test in rat to ED50 in rat spinal nerve ligation model of neuropathic pain	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Kv7 (KCNQ) channel modulators and neuropathic pain.
AID1894939	Anticonvulsant activity in MES induced Kunming mouse model of seizure assessed as EC50 in plasma	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1557154	Agonist activity at human KCNQ2/3 expressed in HEK293 cells by FLIPR based thallium influx assay relative to retigabine	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Design and evaluation of pyrazolopyrimidines as KCNQ channel modulators.
AID1604642	Activation of human Kv7.4 expressed in CHO cells assessed as increase in channel current amplitude by whole cell patch clamp electrophysiology assay
AID1604651	Drug metabolism in human liver S9 fractions assessed as CYP450-mediated phase 1 metabolism at 1 mM preincubated for 5 mins followed by NADPH addition and measured after 60 mins by RP-UHPLC-DAD analysis relative to control
AID1477023	Antagonist activity at NMDA receptor in human IMR90-c4 cells assessed as decrease in NMDA-mediated reduction in cell viability at 30 uM by PrestoBlue assay	2017	Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23	Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1894942	Anticonvulsant activity in Kunming mouse brain assessed as brain EC50 level by rotarod test	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1894951	Neurotoxicity in Kunming mouse assessed as motor impairment rate at 60 mg/kg, po after 1 hr by rotarod test	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1604638	Activation of human Kv7.4 expressed in CHO cells assessed as delta V at 10 uM by whole cell patch clamp electrophysiology assay
AID1874635	Activation of Kv7.2/Kv7.3 channel (unknown origin) expressed in CHO cells at -80 mV measured after 24 hrs by whole cell patch clamp based electrophysiological method
AID1604627	Lipophilicity, log P of the compound
AID1604639	Activation of human Kv7.5 expressed in CHO cells assessed as delta V at 10 uM by whole cell patch clamp electrophysiology assay
AID1868422	Inhibition of KCNQ2/3 (unknown origin) at a holding potential -40 mV at 30 uM by whole cell patch clamp electrophysiology relative to control	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Optimization of 4-arylthiophene-3-carboxylic acid derivatives as inhibitors of ANO1: Lead optimization studies toward their analgesic efficacy for inflammatory pain.
AID1874654	Toxicity in PTZ induced C57BL/6 mouse acute seizure model assessed as mortality at 3 mg/kg, ip
AID1894921	Agonist activity at human KCNQ5 channel expressed in CHO cells assessed as amplitude change of outward current at 10 uM by patch clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1894957	Ratio of TD50 for Kunming mouse to ED50 for anticonvulsant activity in Kunming mouse	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1249436	Permeability in dog RRCK cells after 2 hrs by transwell assay	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Discovery of a novel Kv7 channel opener as a treatment for epilepsy.
AID1586935	Agonist activity at human KCNQ5 expressed in CHOK1 cells by whole cell patch clamp assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity.
AID1604653	Drug metabolism in human liver S9 fractions assessed as assessed as NAT-mediated phase 2 metabolism at 1 mM preincubated for 5 mins followed by NADPH addition and measured after 60 mins by RP-UHPLC-DAD analysis relative to control
AID1874659	Lipophilicity, logP of the compound
AID1874637	Activation of Kv7.2/Kv7.3 channel (unknown origin) expressed in CHO cells at + 80 mV assessed as leftward shift change in half activation potential measured after 24 hrs by whole cell patch clamp based electrophysiological method
AID1586920	Activity at rat KCNQ2 expressed in CHOK1 cells assessed as ratio of amplitude of outward current in presence of test compound to amplitude of outward current in absence of test compound at 10 uM at -10 mV by whole cell patch clamp assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity.
AID779736	Induction of mouse KCNQ2 expressed in HEK293 cells at -40 mV holding potential by whole-cell patch clamp assay	2013	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22	Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl)ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic pain.
AID1894909	Agonist activity at rat KCNQ3 A278T mutant expressed in CHO cells assessed as amplitude change of outward current at 10 uM by patch clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1557153	Agonist activity at human KCNQ2/3 expressed in HEK293 cells by FLIPR based thallium influx assay	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Design and evaluation of pyrazolopyrimidines as KCNQ channel modulators.
AID1634033	Agonist activity at human Kv7.4 expressed in HEK293 cells assessed as drug concentration that doubles the conductance at voltage leading to 15% channel activation at holding potential of at -80 mV by whole cell patch clamp electrophysiology assay
AID1634031	Agonist activity at human Kv7.2/Kv7.3 expressed in HEK293 cells assessed as drug concentration that doubles the conductance at voltage leading to 15% channel activation at holding potential of at -80 mV by whole cell patch clamp electrophysiology assay
AID1604634	Activation of human Kv7.2/Kv7.3 expressed in CHO cells assessed as increase in channel current amplitude by whole cell patch clamp electrophysiology assay
AID624630	Drug glucuronidation reaction catalyzed by human recombinant UGT1A1	2005	Pharmacology & therapeutics, Apr, Volume: 106, Issue:1	UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1495582	Activation of KCNQ2 (unknown origin) expressed in CHO cells assessed as half-maximum activation voltage left shift at 10 uM by electrophysiological patch-clamp test	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents.
AID1874636	Activation of Kv7.2/Kv7.3 channel (unknown origin) expressed in CHO cells at -120 mV measured after 24 hrs by whole cell patch clamp based electrophysiological method
AID1249438	Toxicity in human THLE cells assessed as ATP depletion	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	Discovery of a novel Kv7 channel opener as a treatment for epilepsy.
AID1894956	Anticonvulsant activity in Kunming mouse assessed as reduction in Sc-PTZ induced seizure after 1 hr	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1894945	Neurotoxicity in Kunming mouse assessed as motor impairment rate at 250 mg/kg, po after 1 hr by rotarod test	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1894912	Agonist activity at rat KCNQ2/3 channel expressed in CHO cells assessed as shift of half voltage of maximal activation at 10 uM by patch clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1874658	Ratio of drug concentration in brain to plasma in C57BL/6 mouse at 1 mg/kg, ip measured after 60 mins by UHPLC-MS/MS analysis
AID461907	Antinociceptive activity in formalin-treated Sprague-Dawley rat model assessed as reduction in hind paw flinches at 10 mg/kg, po measured during 11 to 60 mins of phase 2 flinches	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.
AID1894916	Agonist activity at human KCNQ4 channel expressed in CHO cells assessed as shift of half voltage of maximal activation at 10 uM by patch clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1477028	Neuroprotective activity against etoposide-induced apoptosis in rat PC12 cells assessed as increase in Bcl2/Bax ratio at 3 uM pretreated for 4 hrs followed by etoposide challenge measured after 48 hrs by Western blot method	2017	Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23	Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1495578	Activation of KCNQ2 (unknown origin) expressed in CHO cells at 10 uM incubated for 20 mins in dark measured every 2 secs for 10 secs by fluorescence-based thallium influx assay relative to control	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents.
AID1323835	Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by Cheng-Prusoff analysis	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID249628	Relative efficacy as ratio of maximal current amplitudes for compound and reference	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	(S,E)-N-[1-(3-heteroarylphenyl)ethyl]-3-(2-fluorophenyl)acrylamides: synthesis and KCNQ2 potassium channel opener activity.
AID1586941	Effect on voltage-dependent activation of rat KCNQ2 expressed in CHOK1 cells assessed as negative shift in current activation curve at 10 uM by whole cell patch clamp assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity.
AID1604635	Activation of human Kv7.2 expressed in CHO cells assessed as delta V at 10 uM by whole cell patch clamp electrophysiology assay
AID1874631	Metabolic stability in human liver S9 fraction assessed as phase 1 metabolism by UHPLC-MS/MS analysis
AID1477025	Neuroprotective activity against etoposide-induced apoptosis in rat PC12 cells assessed as increase in Bcl2/Bax ratio at 3 uM pretreated for 4 hrs followed by etoposide challenge measured after 24 hrs by Western blot method	2017	Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23	Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID313167	Toxicity in rat by rotarod test	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Kv7 (KCNQ) channel modulators and neuropathic pain.
AID1477031	Induction of autophagy in rat PC12 cells at 3 uM after 48 hrs by MDC staining-based flow cytometric method relative to control	2017	Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23	Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1477020	Neuroprotective activity in rat PC12 cells assessed as decrease in H2O2-induced reactive oxygen species generation at 10 uM by CellROX/DAPI-blue staining-based fluorescence microscopic method	2017	Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23	Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1604647	Photostability of compound in pH 7.4 buffer assessed as formation of ethyl (2,4-bis((4-fluorobenzyl)amino)phenyl)carbamate by measuring retention time of metabolite incubated for 6 hrs under visible light irradiation by HPLC/MS analysis
AID1477021	Neuroprotective activity against H2O2-induced apoptosis in rat PC12 cells assessed as increase in cell viability at 1 to 30 uM after 4 hrs by PrestoBlue assay	2017	Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23	Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1894908	Agonist activity at rat KCNQ3 A278T mutant expressed in CHO cells assessed as shift of half voltage of maximal activation at 10 uM by patch clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1477016	Neuroprotective activity against etoposide-induced apoptosis in human IMR90-c4 cells assessed as increase in cell viability at 10 to 30 uM pretreated for 4 hrs followed by etoposide challenge measured after 36 hrs by PrestoBlue assay	2017	Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23	Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID624633	Drug glucuronidation reaction catalyzed by human recombinant UGT1A4	2005	Pharmacology & therapeutics, Apr, Volume: 106, Issue:1	UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1604644	Photostability of compound in pH 7.4 buffer assessed as compound degradation at 100 ug/ml incubated for 6 hrs under UV-irradiation at wavelength of 365 and 264 nm by HPLC analysis
AID461912	Analgesic activity in Sprague-Dawley rat assessed as reduction of spinal nerve ligation-induced allodynia score at 10 mg/kg, po	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.
AID1604661	Half life in human
AID1894960	Anticonvulsant activity in C57BL/6 mouse 6 Hz seizure model at 44 mA measured after 1 hr	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1586934	Agonist activity at human KCNQ4 expressed in CHOK1 cells by whole cell patch clamp assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity.
AID1604628	Hydrophobicity of compound assessed as self aggregating property by measuring decrease in ratio between fluorescence intensity peaks at 372 nm to 383 nm at 0.7 to 100 uM by pyrene based fluorescence spectroscopic method
AID1604650	Photostability of compound in pH 7.4 buffer assessed as compound degradation at 100 ug/ml incubated for 4 hrs under natural solar light-irradiation by HPLC analysis relative to control
AID1894934	Drug concentration in Kunming mouse brain at 100 mg/kg	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1604637	Activation of human Kv7.3 expressed in CHO cells assessed as delta V at 30 uM by whole cell patch clamp electrophysiology assay
AID1398550	Channel opening activity at KCNQ2 (unknown origin) expressed in CHO cells at 10 uM incubated for 20 mins in dark measured every 2 secs for 10 secs by fluorescence-based thallium influx assay relative to control	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy.
AID461908	Antinociceptive activity in formalin-treated Sprague-Dawley rat model assessed as reduction in hind paw flinches at 17 mg/kg, po measured during 11 to 60 mins of phase 2 flinches	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.
AID1894935	Drug concentration in Kunming mouse plasma at 100 mg/kg	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID246197	Effective concentration against whole-cell patch clamp from mouse HEK293 cells	2004	Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17	Synthesis and KCNQ2 opener activity of N-(1-benzo[1,3]dioxol-5-yl-ethyl, N-[1-(2,3-dihydro-benzofuran-5-yl)-ethyl, and N-[1-(2,3-dihydro-1H-indol-5-yl)-ethyl acrylamides.
AID313160	Analgesic activity in CCI and SNL nerve injury in po dosed rat model of pain	2007	Journal of medicinal chemistry, May-31, Volume: 50, Issue:11	Kv7 (KCNQ) channel modulators and neuropathic pain.
AID1398552	Anticonvulsant activity in maximal electroshock induced Kunming mouse assessed as epilepsy incidence at 25 mg/kg, ip measured after 30 mins	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy.
AID1604646	Photostability of compound in pH 7.4 buffer assessed as compound degradation at 100 ug/ml incubated for 6 hrs under natural solar light-irradiation by HPLC analysis relative to control
AID1861510	Agonist activity at Kv7.2 (unknown origin) assessed as shifting of voltage dependent activation to more negative potentials by SyncroPatch assay relative to control	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Development of an automated screen for Kv7.2 potassium channels and discovery of a new agonist chemotype.
AID1861511	Agonist activity at Kv7.2 W236L mutant (unknown origin) assessed as shifting of voltage dependent activation to more negative potentials by SyncroPatch assay relative to control	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Development of an automated screen for Kv7.2 potassium channels and discovery of a new agonist chemotype.
AID1874660	Half life in C57BL/6 mouse plasma at 3 mg/kg, ip measured upto 24 hrs by UHPLC-MS/MS analysis
AID1323834	Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by scintillation proximity assay	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID1634034	Agonist activity at human Kv7.4/Kv7.5 expressed in HEK293 cells assessed as drug concentration that doubles the conductance at voltage leading to 15% channel activation at holding potential of at -80 mV by whole cell patch clamp electrophysiology assay
AID1894946	Neurotoxicity in Kunming mouse assessed as motor impairment rate at 300 mg/kg, po after 1 hr by rotarod test	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1861508	Agonist activity at Kv7.2 (unknown origin) assessed as shifting of voltage dependent activation to more negative potentials at 5 uM by SyncroPatch assay	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Development of an automated screen for Kv7.2 potassium channels and discovery of a new agonist chemotype.
AID1604640	Activation of human Kv7.2 expressed in CHO cells assessed as increase in channel current amplitude by whole cell patch clamp electrophysiology assay
AID587713	Activation of human KCNQ2/Q3 expressed in CHO cells assessed as increase in channel current at -40 mV holding potential at 10 uM by whole cell patch-clamp assay	2011	European journal of medicinal chemistry, Mar, Volume: 46, Issue:3	Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.
AID587717	Activation of KCNQ1 expressed in HEK293 cells upto 100 uM by atomic absorption Rb'+ efflux assay	2011	European journal of medicinal chemistry, Mar, Volume: 46, Issue:3	Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.
AID1894926	Anticonvulsant activity in MES induced Kunming mouse model of seizure at 30 mg/kg, po after 1 hr	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
AID1874647	Anticonvulsant activity in PTZ induced C57BL/6 mouse acute seizure model assessed as time for maximal seizure at 3 mg/kg, ip pretreated for 30 mins followed by PTZ injection and measured upto 30 mins by Liittjohann's scale analysis
AID1346689	Human Kv7.5 (Voltage-gated potassium channels)	2002	European journal of pharmacology, Feb-22, Volume: 437, Issue:3	Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352.
AID1346713	Human Kv7.3 (Voltage-gated potassium channels)	2001	The Journal of neuroscience : the official journal of the Society for Neuroscience, Aug-01, Volume: 21, Issue:15	Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
AID1346699	Human Kv7.4 (Voltage-gated potassium channels)	2001	The Journal of neuroscience : the official journal of the Society for Neuroscience, Aug-01, Volume: 21, Issue:15	Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
AID1346696	Human Kv7.2 (Voltage-gated potassium channels)	2001	The Journal of neuroscience : the official journal of the Society for Neuroscience, Aug-01, Volume: 21, Issue:15	Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	12 (3.20)	18.2507
2000's	106 (28.27)	29.6817
2010's	210 (56.00)	24.3611
2020's	47 (12.53)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	26 (6.79%)	5.53%
Reviews	44 (11.49%)	6.00%
Case Studies	7 (1.83%)	4.05%
Observational	3 (0.78%)	0.25%
Other	303 (79.11%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (25)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Developing Neuronal KCNQ Channel Modulators for Mood Disorders [NCT03043560]	Phase 2	45 participants (Actual)	Interventional	2017-09-25	Completed
A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults With Partial-Onset Seizures (Extension of Study RGB113905) [NCT01336621]	Phase 3	98 participants (Actual)	Interventional	2011-02-21	Completed
An Interaction Study to Assess the Effect of the Ezogabine/Retigabine and the Main Metabolite NAMR on the Pharmacokinetics of Digoxin in Healthy Volunteers [NCT01583036]	Phase 1	30 participants (Actual)	Interventional	2012-01-16	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures [NCT00232596]	Phase 3	306 participants (Actual)	Interventional	2005-09-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated With Post-Herpetic Neuralgia [NCT00612105]	Phase 2	187 participants (Actual)	Interventional	2007-10-31	Completed
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301) [NCT00310375]	Phase 3	181 participants (Actual)	Interventional	2006-05-01	Completed
Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Se [NCT00235755]	Phase 3	539 participants (Actual)	Interventional	2005-12-31	Completed
A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302) [NCT00310388]	Phase 3	376 participants (Actual)	Interventional	2006-07-05	Terminated(stopped due to No longer any benefit in collecting data since retigabine has been withdrawn from market.)
An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures [NCT01227902]	Phase 3	203 participants (Actual)	Interventional	2010-07-31	Completed
An Open-Label Extension of the Study XEN496 in Children With KCNQ2 Developmental and Epileptic Encephalopathy [NCT04912856]	Phase 3	8 participants (Actual)	Interventional	2021-08-17	Terminated(stopped due to Sponsor decision; not a safety decision)
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome [NCT01494584]	Phase 2	5 participants (Actual)	Interventional	2012-07-25	Terminated(stopped due to Terminated after placing the study on hold at the request of the FDA)
A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis [NCT02450552]	Phase 2	65 participants (Actual)	Interventional	2015-06-30	Completed
An Open Label, Single-dose, Fixed Sequence, Two Treatment Period Study to Assess the Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR). [NCT01480609]	Phase 1	8 participants (Actual)	Interventional	2011-11-30	Completed
A Phase 3 Study of Adjunctive XEN496 in Pediatric Subjects With KCNQ2 Developmental and Epileptic Encephalopathy [NCT04639310]	Phase 3	8 participants (Actual)	Interventional	2021-03-29	Terminated(stopped due to Sponsor decision; Not a safety decision)
Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study [NCT01823159]	Phase 3	15 participants (Actual)	Interventional	2013-04-30	Completed
An Open-label, Single Centre, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects [NCT01691872]	Phase 1	0 participants (Actual)	Interventional	2012-10-10	Withdrawn(stopped due to Development plan of retigabine XR in Japan was readjusted.)
An Open-label, Randomized, Single Centre, 4-way Crossover Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ezogabine/Retigabine in Healthy Adult Taiwanese Subjects [NCT01462669]	Phase 1	1 participants (Actual)	Interventional	2012-04-10	Completed
A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (Extension of Study RTG114855) [NCT01777139]	Phase 3	30 participants (Actual)	Interventional	2013-04-11	Completed
Meta-Analysis of VRX-RET-E22-303 and VRX-RET-E22-304: Two Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Studies of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extensions of Studies VRX-RET-E22-301 and VRX-RET [NCT01457989]		1 participants (Actual)	Observational	2011-08-31	Completed
RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects With Partial Onset Seizures (>= 12 Years Old) and Subjects With Lennox-Gastaut Syndrome (>=12 Years Old) [NCT01668654]	Phase 3	4 participants (Actual)	Interventional	2012-09-04	Terminated(stopped due to FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in subjects; early termination allows for timely reporting of results.)
A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resi [NCT01648101]	Phase 3	76 participants (Actual)	Interventional	2012-08-29	Terminated(stopped due to Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam)
Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy [NCT01587339]		6,498 participants (Actual)	Observational	2010-09-30	Completed
A Proof-Of-Concept Clinical Trial of a Novel KCNQ Potentiator in Major Depressive Disorder [NCT02149836]	Phase 2	18 participants (Actual)	Interventional	2014-08-31	Completed
Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets Versus Placebo in the Adjunctive Treatment of Subjects With Partial-Onset Seizures [NCT01721317]	Phase 4	6 participants (Actual)	Interventional	2012-12-19	Terminated(stopped due to After reevaluation of the benefit: risk profile of ezogabine/retigabine, GSK does not believe the early adjunctive treatment study population is appropriate.)
An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures [NCT01607346]	Phase 4	10 participants (Actual)	Interventional	2013-03-27	Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00232596 (20) [back to overview]	Number of Participants Reporting New Seizure Types in the Indicated Categories During the DB Phase (Titration and Maintenance Phases) That Were Not Reported at Baseline
NCT00232596 (20) [back to overview]	Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories
NCT00232596 (20) [back to overview]	Number of Participants Who Experienced the Indicated Level of Exacerbation and Reduction in the 28-day Total Partial Seizure Frequency From Baseline During the Maintenance Phase
NCT00232596 (20) [back to overview]	Number of Participants Who Reported the Indicated Renal and Urinary Disorder Adverse Events at a Frequency Threshold of 2% (in Any Treatment Arm)
NCT00232596 (20) [back to overview]	Number of Participants Who Were Responders and Non-responders in the DB Phase
NCT00232596 (20) [back to overview]	Number of Participants Who Were Responders and Non-responders in the Maintenance Phase
NCT00232596 (20) [back to overview]	Number of Participants Who Were Seizure-free During the DB Phase (Titration and Maintenance Phases)
NCT00232596 (20) [back to overview]	Number of Participants Who Were Seizure-free During the Maintenance Phase
NCT00232596 (20) [back to overview]	Number of Participants Whose Clinical Laboratory Values Were Deemed an Adverse Event by the Investigator (>=2% in Any Treatment Arm)
NCT00232596 (20) [back to overview]	Number of Participants With a >=7% Increase in Body Weight During Weeks 2, 4, and 6 of theTitration Phase and Weeks 7, 8, 10, 14, and 18 of the Maintenance Phase
NCT00232596 (20) [back to overview]	Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of the DB Phase (Titration and Maintenance Phases) by Indicated Decile Reduction and Increase Categories
NCT00232596 (20) [back to overview]	Number of Participants With the Indicated Reduction From Baseline in the 28-day Total Partial Seizure Frequency During the Maintenance Phase
NCT00232596 (20) [back to overview]	Quality of Life (QOL) Assessed by QOL in Epilepsy-Problems Questionnaire (QOLIE-31-P) at Baseline (Week 0) and Weeks 6, 10, and 18
NCT00232596 (20) [back to overview]	Clinical Global Impression-Improvement (CGI-I) Score at the End of the Maintenance Phase
NCT00232596 (20) [back to overview]	Patient Global Impression (PGI) Score at the End of the Maintenance Phase
NCT00232596 (20) [back to overview]	Percent Change From Baseline (BL) in the 28-day Total Partial Seizure Frequency During the Maintenance Phase
NCT00232596 (20) [back to overview]	Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)
NCT00232596 (20) [back to overview]	Percentage of Seizure-free Days During the DB Phase (Titration and Maintenance Phases)
NCT00232596 (20) [back to overview]	Percentage of Seizure-free Days During the Maintenance Phase
NCT00232596 (20) [back to overview]	Change From Baseline in Post-void Residual Urine Volume at Weeks 10 and 18 of the DB Treatment Phase
NCT00235755 (20) [back to overview]	Number of Participants Who Were Responders and Non-responders During the DB Phase
NCT00235755 (20) [back to overview]	Number of Participants Who Were Seizure-free During the DB Phase (Titration and Maintenance Phases)
NCT00235755 (20) [back to overview]	Number of Participants Who Were Seizure-free During the Maintenance Phase
NCT00235755 (20) [back to overview]	Number of Participants Whose Clinical Laboratory Values Were Deemed an Adverse Event by the Investigator (>=2% in Any Treatment Arm)
NCT00235755 (20) [back to overview]	Number of Participants With a >=7% Increase in Body Weight During Weeks 2 and 4 of theTitration Phase and Weeks 6, 8, 12, and 16 of the Maintenance Phase
NCT00235755 (20) [back to overview]	Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the DB Phase (Titration and Maintenance Phases) by Indicated Decile Reduction and Increase Categories
NCT00235755 (20) [back to overview]	Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories
NCT00235755 (20) [back to overview]	Number of Participants With the Indicated Reduction From Baseline in the 28-day Total Partial Seizure Frequency During the Maintenance Phase
NCT00235755 (20) [back to overview]	Quality of Life Assessed by Quality of Life in Epilepsy-Problems Questionnaire (QOLIE-31-P) at BL (Week 0) and Weeks 4, 8, and 16
NCT00235755 (20) [back to overview]	Patient Global Impression (PGI) Score at the End of the Maintenance Phase
NCT00235755 (20) [back to overview]	Percent Change From Baseline (BL) in the 28-day Total Partial Seizure Frequency During the Maintenance Phase
NCT00235755 (20) [back to overview]	Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)
NCT00235755 (20) [back to overview]	Percentage of Seizure-free Days During the DB Phase (Titration and Maintenance Phases)
NCT00235755 (20) [back to overview]	Percentage of Seizure-free Days During the Maintenance Phase
NCT00235755 (20) [back to overview]	Change From Baseline in Post-void Residual Urine Volume at Weeks 8 and 16 of the Maintenance Phase
NCT00235755 (20) [back to overview]	Number of Participants Classified as Responders and Non-responders During the Maintenance Phase
NCT00235755 (20) [back to overview]	Number of Participants Reporting New Seizure Types in the Indicated Categories During the DB Phase (Titration and Maintenance Phases) That Were Not Reported at Baseline
NCT00235755 (20) [back to overview]	Number of Participants Who Experienced the Indicated Level of Exacerbation and Reduction in the 28-day Total Partial Seizure Frequency From Baseline During the Maintenance Phase
NCT00235755 (20) [back to overview]	Clinical Global Impression-Improvement (CGI-I) Score at the End of the Maintenance Phase
NCT00235755 (20) [back to overview]	Number of Participants Who Reported the Indicated Renal and Urinary Disorder Adverse Events at a Frequency Threshold of 2% (in Any Treatment Arm)
NCT00310375 (39) [back to overview]	Number of Participants Who Were Seizure Free for Any 12 Continuous Months
NCT00310375 (39) [back to overview]	Number of Participants Who Were Seizure Free for Any 6 Continuous Months
NCT00310375 (39) [back to overview]	Number of Participants With a Decrease in Confrontational Visual Field From Initial Examination
NCT00310375 (39) [back to overview]	Number of Participants With Pigmentation of Non-retinal Ocular Tissue
NCT00310375 (39) [back to overview]	Number of Participants With Pigmentation of Retinal Ocular Tissue
NCT00310375 (39) [back to overview]	Number of Participants With Resolution of Dermatologist Confirmed Abnormal Discoloration After Discontinuation of Retigabine
NCT00310375 (39) [back to overview]	Number of Participants With Treatment-emergent Adverse Events Leading to Withdrawal From Study Drug
NCT00310375 (39) [back to overview]	Number of Responders
NCT00310375 (39) [back to overview]	Change From Baseline in Heart Rate
NCT00310375 (39) [back to overview]	Change From Baseline in Hematology Parameter-Red Blood Cell Count
NCT00310375 (39) [back to overview]	Change From Baseline in Hematology Parameters- Bands, Basophils, Eosinophils, Lymphocytes, Metamyelocyte, Monocytes, Neutrophils, Platelets, White Blood Cells Count (WBC)
NCT00310375 (39) [back to overview]	Change From Baseline in Overall American Urological Association (AUA) Symptom Index Score
NCT00310375 (39) [back to overview]	Change From Baseline in Post-void Residual Bladder Ultrasound Volume
NCT00310375 (39) [back to overview]	Change From Baseline in Quality of Life in Epilepsy (QOLIE)-31-P Questionnaire
NCT00310375 (39) [back to overview]	Change From Baseline in the 12-lead Electrocardiogram (ECG) Parameter-RR Interval
NCT00310375 (39) [back to overview]	Change From Baseline in the 12-lead Electrocardiogram (ECG) Parameters-PR Interval, QRS Duration, Uncorrected QT (uQT) Interval, Corrected QT (Bazett's Correction) Interval (QTcB), Corrected QT (Friedericia's Correction) Interval (QTcF)
NCT00310375 (39) [back to overview]	Change From Baseline in Urine Power of Hydrogen (pH)
NCT00310375 (39) [back to overview]	Change From Baseline in Urine Specific Gravity
NCT00310375 (39) [back to overview]	Change From Baseline in Weight
NCT00310375 (39) [back to overview]	Kaplan-Meier Estimate of the Probability of Discontinuation (d/c) From Study Drug
NCT00310375 (39) [back to overview]	Number of Participants With Abnormal Pigmentation of Skin, Including the Skin Around the Eyes and the Eyelids, Lips, Nails, or Mucosa
NCT00310375 (39) [back to overview]	Number of Participants With Abnormal Results in Physical Examination
NCT00310375 (39) [back to overview]	Number of Participants With Abnormal Results of Neurological Examination
NCT00310375 (39) [back to overview]	Number of Participants With Resolution of Abnormal Eye Pigmentation After Discontinuation of Retigabine
NCT00310375 (39) [back to overview]	Number of Participants With Treatment-emergent Serious Adverse Event (SAE) and Adverse Event (AE)
NCT00310375 (39) [back to overview]	Time From Discontinuation of Retigabine to Resolution of Abnormal Eye Pigmentation
NCT00310375 (39) [back to overview]	Time From Discontinuation of Retigabine to Resolution of All Dermatologist-Confirmed Abnormal Discoloration
NCT00310375 (39) [back to overview]	Percentage Change From Baseline in the 28-day Partial Seizure
NCT00310375 (39) [back to overview]	Percentage of Seizure-free Days
NCT00310375 (39) [back to overview]	Change From Baseline in Blood Pressure
NCT00310375 (39) [back to overview]	Change From Baseline in Body Temperature
NCT00310375 (39) [back to overview]	Change From Baseline in Chemistry Parameter-Total Protein
NCT00310375 (39) [back to overview]	Change From Baseline in Chemistry Parameters -Creatinine, Total Bilirubin (TB), Uric Acid (UA)
NCT00310375 (39) [back to overview]	Change From Baseline in Chemistry Parameters-Alkaline Phosphatase (AP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST)
NCT00310375 (39) [back to overview]	Change From Baseline in Chemistry Parameters-Bicarbonate, Blood Urea Nitrogen (BUN), Calcium, Chloride, Cholesterol, Non-fasting Glucose, Phosphorus, Potassium, Sodium, Urea
NCT00310375 (39) [back to overview]	Change From Baseline in Electrocardiogram (ECG) Parameter-QRS Axis
NCT00310375 (39) [back to overview]	Change From Baseline in Haematocrit
NCT00310375 (39) [back to overview]	Change From Baseline in Haemoglobin
NCT00310375 (39) [back to overview]	Number of Participants With a Clinically Significant Decrease in Visual Acuity From Initial Examination
NCT00310388 (37) [back to overview]	Change From Baseline in Body Weight
NCT00310388 (37) [back to overview]	Change From Baseline in Body Temperature
NCT00310388 (37) [back to overview]	Change From Baseline in Bicarbonate, Calcium, Chloride, Cholesterol, Non-fasting Glucose, Phosphorus, Potassium, Sodium and Urea
NCT00310388 (37) [back to overview]	Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, White Blood Cells (WBC)
NCT00310388 (37) [back to overview]	Change From Baseline in Alkaline Phosphatase (Alk. Phos.), Alanine Amino Transferase (ALT) and Aspartate Amino Transferase (AST)
NCT00310388 (37) [back to overview]	Percentage of Seizure Free Days
NCT00310388 (37) [back to overview]	Percentage of Participants With Decrease in Confrontation Visual Field From Initial Examination
NCT00310388 (37) [back to overview]	Percentage of Participants With 50% Reduction in Seizure Frequency From Baseline Phase of the Parent Study (VRX-RET-E22-302) to Open Label Treatment
NCT00310388 (37) [back to overview]	Change From Baseline in Electocardiogram (ECG) Parameters PR, QRS, QT, Corrected QT Interval (QTc) Bazett and QTc Friedericia
NCT00310388 (37) [back to overview]	Number of Participants With TEAEs Leading to Treatment Discontinuation (Disc.)
NCT00310388 (37) [back to overview]	Number of Participants Who Were Seizure Free for Any 12 Continuous Months
NCT00310388 (37) [back to overview]	Number of Participants Who Were Seizure Free for Any 6 Continuous Months
NCT00310388 (37) [back to overview]	Number of Participants With Resolution of Dermatologist Confirmed Abnormal Discoloration After Discontinuation of Retigabine
NCT00310388 (37) [back to overview]	Change From Baseline in Urine Potential of Hydrogen (pH)
NCT00310388 (37) [back to overview]	Change From Baseline in Hematocrit
NCT00310388 (37) [back to overview]	Change From Baseline in Hematology Parameter Red Blood Cells (RBC)
NCT00310388 (37) [back to overview]	Change From Baseline in Hemoglobin
NCT00310388 (37) [back to overview]	Change From Baseline in Post-Void Residual (PVR) Bladder Ultrasound Volume
NCT00310388 (37) [back to overview]	Change From Baseline in Quality of Life in Epilepsy-31-Problems (QOLIE-31-P) Questionnaire
NCT00310388 (37) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Measurements in the Supine and Standing Position
NCT00310388 (37) [back to overview]	Change From Baseline in the Urinary Voiding Function [UVF] (Assessed Using the American Urological Association [AUA] Symptom Index)
NCT00310388 (37) [back to overview]	Change From Baseline in Total Protein
NCT00310388 (37) [back to overview]	Change From Baseline in Urine Specific Gravity
NCT00310388 (37) [back to overview]	Kaplan-Meier Estimate of the Probability of Disc. From Study Drug
NCT00310388 (37) [back to overview]	Number of Participants With Resolution of Abnormal Eye Pigmentation After Discontinuation of Retigabine
NCT00310388 (37) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)
NCT00310388 (37) [back to overview]	Percentage of Participants With a Clinically Significant Decrease (CSD) in Visual Acuity (VA) From Initial Examination
NCT00310388 (37) [back to overview]	Percentage of Participants With Abnormal Pigmentation of Skin, Including the Skin Around the Eyes and the Eyelids, Lips, Nails, or Mucosa
NCT00310388 (37) [back to overview]	Percentage of Participants With Abnormal Results of Neurological Examination
NCT00310388 (37) [back to overview]	Change From Baseline in Heart Rate (HR) Measurements in the Supine and Standing Position
NCT00310388 (37) [back to overview]	Percentage of Participants With Abnormal Results of Physical Examination
NCT00310388 (37) [back to overview]	Percentage of Participants With Pigmentation of Non-retinal Ocular Tissue (Non-ret. Pig. Abn)
NCT00310388 (37) [back to overview]	Percentage of Participants With Retinal Pigmentary Abnormalities (RPA)
NCT00310388 (37) [back to overview]	Time From Discontinuation of Retigabine to Resolution of Abnormal Eye Pigmentation
NCT00310388 (37) [back to overview]	Time From Discontinuation of Retigabine to Resolution of All Dermatologist-Confirmed Abnormal Discoloration
NCT00310388 (37) [back to overview]	Percentage Change in the 28-day Partial Seizure Rate From the Baseline Phase (Obtained During the 8-week Baseline Period of Study VRX-RET-E22-302) to Open-label Treatment.
NCT00310388 (37) [back to overview]	Change From Baseline in Creatinine, Total Bilirubin and Uric Acid
NCT00612105 (23) [back to overview]	Scores for Reported Health Transition at the End of the MP for All Participants Who Completed Week 4 of the MP and Who Terminated Early During the MP
NCT00612105 (23) [back to overview]	"Change From Baseline in the Average Diary Pain Score to the Last 7 Days of the Maintenance Phase by Post Herpetic Neuralgia (PHN) Subtype Deafferentation Type 2 (D Type 2)"
NCT00612105 (23) [back to overview]	"Change From Baseline in the Average Diary Pain Score to the Last 7 Days of the Maintenance Phase by Post Herpetic Neuralgia (PHN) Subtype Irritable Nociceptors"
NCT00612105 (23) [back to overview]	"Change From Baseline in the Average Diary Pain Score to the Last 7 Days of the Maintenance Phase by Post Herpetic Neuralgia (PHN) Subtype Unclassifiable"
NCT00612105 (23) [back to overview]	"Change From Baseline in the Average Diary Pain Score to the Last 7 Days of the Maintenance Phase by Post Herpetic Neuralgia (PHN) SubtypeDeafferentation Type 1 (D Type 1)"
NCT00612105 (23) [back to overview]	Change From Baseline to the End of the MP (Included All Participants Who Completed Week 4 of the MP and Who Terminated Early During the MP) in Sleep Quantity
NCT00612105 (23) [back to overview]	Primary Endpoint Will be the Change From Baseline in Average Pain Score Over the Last 7 Days of the Maintenance Phase.
NCT00612105 (23) [back to overview]	"Number of Participants With the Indicated Responses at Baseline to the Questions of Is it Cool? and Is it Painful? in an Assessment of Cold Threshold and Allodynia"
NCT00612105 (23) [back to overview]	"Number of Participants With the Indicated Responses at the End of the MP to the Question: How Painful Was the Affected Side Compared to the Opposite Side? in an Assessment of Tactile Allodynia"
NCT00612105 (23) [back to overview]	"Number of Participants With the Indicated Responses at the End of the MP to the Questions of Is it Cool? and Is it Painful? in an Assessment of Cold Threshold and Allodynia"
NCT00612105 (23) [back to overview]	"Number of Subjects With the Indicated Responses at Baseline to the Questions: How Sharp Was the Affected Side Compared to the Opposite Side? and How Painfule Was the Affected Side Compared to the Opposite Side? in an Assessment of Hyperalgesia"
NCT00612105 (23) [back to overview]	Change From Baseline in Pain Intensity Score at Each Week During the Maintenance Phase (MP)
NCT00612105 (23) [back to overview]	Change From Baseline to the End of the MP (Included All Participants Who Completed Week 4 of the MP and Who Terminated Early During the MP) in Medical Outcomes Study (MOS) Sleep Scale Scores
NCT00612105 (23) [back to overview]	Change From Baseline to Weeks 2 and 4 of the Maintenance Phase in Mean In-clinic Pain Assessment
NCT00612105 (23) [back to overview]	Mean Score on the Treatment Satisfaction Questionnaire for Medication (TSQM) at the End of the Maintenance Phase
NCT00612105 (23) [back to overview]	Number of Participants Classified as Responders, With a 50% and 30% Pain Reduction From Baseline to the Last 7 Days of the Maintenance Phase
NCT00612105 (23) [back to overview]	Number of Participants With the Indicated Change From Baseline to the End of the Maintenance Phase in Optimal Sleep Based on the Sleep Quantity Domain of the MOS Sleep Scale
NCT00612105 (23) [back to overview]	Number of Rescue Medication Tablets Taken Per Day During the Maintenance Phase (MP)
NCT00612105 (23) [back to overview]	Scores on the Brief Pain Inventory-Short Form (BPI-SF) at the End of the MP for All Participants Who Completed Week-4 of the MP and Who Terminated Early During the MP
NCT00612105 (23) [back to overview]	Scores on the Medical Outcomes Short Form-36 (SF-36) at the End of the MP for All Participants Who Completed Week 4 of the MP and Who Terminated Early During the MP
NCT00612105 (23) [back to overview]	"Number of Participants With Indicated Responses at the End of the MP to the Questions: How Sharp Was the Affected Side Compared to the Opposite Side? and How Painful Was the Affected Side Compared to the Opposite Side? in an Assessment of Hyperalgesia"
NCT00612105 (23) [back to overview]	"Number of Participants With the Indicated Responses at Baseline to the Question: How Painful Was the Affected Side Compared to the Opposite Side? in an Assessment of Tactile Allodynia"
NCT00612105 (23) [back to overview]	Number of Participants With the Indicated Overall Patient Global Impression of Change (PGIC)
NCT01227902 (17) [back to overview]	Change From Baseline in the PGI-C Score: Current Ability to do the Things You Need to do
NCT01227902 (17) [back to overview]	Change From Baseline in the PGI-C Score: Current Ability to do the Things You Want to do
NCT01227902 (17) [back to overview]	Change From Baseline in the PGI-C Score: Epilepsy-related Worry
NCT01227902 (17) [back to overview]	Change From Baseline in the SF-36v2 Mental Component Summary Score at Week 20/Early Withdrawal
NCT01227902 (17) [back to overview]	Change From Baseline in the SF-36v2 Physical Component Summary Score at Week 20/Early Withdrawal
NCT01227902 (17) [back to overview]	Functional Status Diary (FSD): Percent Change From Baseline in Epilepsy-related Limitation of Ability to do What You Needed to
NCT01227902 (17) [back to overview]	Functional Status Diary (FSD): Percent Change From Baseline in Epilepsy-related Limitation of Ability to do What You Wanted to
NCT01227902 (17) [back to overview]	Functional Status Diary (FSD): Percent Change From Baseline in Epilepsy-related Worry
NCT01227902 (17) [back to overview]	Number of Participants With a >=50% Reduction in Partial-onset Seizure (POS) Frequency From Baseline
NCT01227902 (17) [back to overview]	Percent Change From Baseline in Functional Status: Percentage of Days With no Missed Work or School Time
NCT01227902 (17) [back to overview]	Percent Change From Baseline in Partial-onset Seizure Frequency
NCT01227902 (17) [back to overview]	Change From Baseline in the Short Form 36 Health Survey, Version 2 (SF-36v2) Domain Scores at Week 20/Early Withdrawal
NCT01227902 (17) [back to overview]	Number of Participants With a >=25%, >=75%, or 100% Reduction in Partial-onset Seizure Frequency From Baseline
NCT01227902 (17) [back to overview]	Number of Participants With the Indicated Reduction or Increase From Baseline in Partial-onset Seizure Frequency
NCT01227902 (17) [back to overview]	Number of Participants With the Indicated Response for the Current Ability to do the Things You Need to do Component of the PGI-C Score
NCT01227902 (17) [back to overview]	Number of Participants With the Indicated Response for the Current Ability to do the Things You Want to do Component of the PGI-C Score
NCT01227902 (17) [back to overview]	Number of Participants With the Indicated Response for the Epilepsy-related Worry Component of the Patient Global Impression of Change (PGI-C) Score
NCT01336621 (43) [back to overview]	Time From Discontinuation of Retigabine to Resolution of All Dermatologist-confirmed Abnormal Discoloration
NCT01336621 (43) [back to overview]	Number of Participants Experiencing New Seizure Types
NCT01336621 (43) [back to overview]	Duration of Retigabine Exposure
NCT01336621 (43) [back to overview]	Number of Participants Experiencing an Increase in 28-day Partial-onset Seizure Frequency From Baseline
NCT01336621 (43) [back to overview]	Number of Participants Experiencing Worsening of Seizures
NCT01336621 (43) [back to overview]	Number of Participants With a Clinically Significant Decrease in Visual Acuity From Initial Examination
NCT01336621 (43) [back to overview]	Number of Participants With Decrease in Confrontational Visual Field From Initial Examination
NCT01336621 (43) [back to overview]	Number of Participants With Pigmentation of Non-retinal Ocular Tissue(s)
NCT01336621 (43) [back to overview]	Number of Participants With Resolution of Dermatologist Confirmed Abnormal Discoloration After Discontinuation of Retigabine
NCT01336621 (43) [back to overview]	Number of Participants With Retinal Pigmentary Abnormalities
NCT01336621 (43) [back to overview]	Number of Participants Withdrawn Due to TEAEs
NCT01336621 (43) [back to overview]	Percent Change From Baseline in 28-day Partial-onset Seizure Frequency
NCT01336621 (43) [back to overview]	Change From Baseline in Absolute Basophils, Absolute Eosinophils, Absolute Lymphocytes, Absolute Monocytes, Absolute Total Neutrophils, Platelet Count and WBC Count
NCT01336621 (43) [back to overview]	Change From Baseline in Albumin and Total Protein
NCT01336621 (43) [back to overview]	Change From Baseline in Alk. Phosphatase, ALT, AST, Creatine Kinase and LD Levels
NCT01336621 (43) [back to overview]	Change From Baseline in BUN/Creatinine Ratio
NCT01336621 (43) [back to overview]	Change From Baseline in Calcium, Chloride, CO2, Glucose, Potassium, Magnesium, Sodium and BUN
NCT01336621 (43) [back to overview]	Change From Baseline in Direct Bilirubin, Total Bilirubin and Creatinine
NCT01336621 (43) [back to overview]	Change From Baseline in ECG Parameter Including PR Interval, QRS Duration, Uncorrected QT Interval, Corrected QT by Bazett's Formula (QTcB), Corrected QT by Fridericia's Formula (QTcF) and RR Interval
NCT01336621 (43) [back to overview]	Change From Baseline in Electrocardiogram (ECG) Parameter Including HR
NCT01336621 (43) [back to overview]	Change From Baseline in Hematocrit Levels
NCT01336621 (43) [back to overview]	Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Levels
NCT01336621 (43) [back to overview]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Levels
NCT01336621 (43) [back to overview]	Change From Baseline in Mean Corpuscle Volume (MCV) and Mean Platelet Volume (MPV) Levels
NCT01336621 (43) [back to overview]	Change From Baseline in Percent Basophils, Percent Eosinophils, Percent Lymphocytes, Percent Monocytes, Percent Neutrophils and RBC Distribution Width (RDW) Levels
NCT01336621 (43) [back to overview]	Change From Baseline in Post-Void Residual (PVR) Bladder Ultrasound Urine Volume
NCT01336621 (43) [back to overview]	Change From Baseline in RBC Count
NCT01336621 (43) [back to overview]	Change From Baseline in Urine Albumin Creatinine Ratio
NCT01336621 (43) [back to overview]	Change From Baseline in Urine Albumin Levels
NCT01336621 (43) [back to overview]	Change From Baseline in Urine Creatinine Levels
NCT01336621 (43) [back to overview]	Changes From Baseline in American Urological Association Symptom Scale (AUA SS) Score
NCT01336621 (43) [back to overview]	Number of Participants Experiencing a 0 to <25, 25 to <50, 50 to <75 and 75 to 100 Percent Reduction in 28 Day POS Frequency From Baseline
NCT01336621 (43) [back to overview]	Number of Participants Who Remained Seizure-free
NCT01336621 (43) [back to overview]	Number of Participants With Abnormal Discoloration of Skin
NCT01336621 (43) [back to overview]	Number of Participants With AEs and SAEs: All SFUCP Subjects
NCT01336621 (43) [back to overview]	Number of Participants With Clinical Chemistry Parameters of PCC
NCT01336621 (43) [back to overview]	Number of Participants With Hematology Parameters of PCC
NCT01336621 (43) [back to overview]	Number of Participants With Potential Clinical Concern (PCC) Values of Change From Baseline in Vital Signs and Weight
NCT01336621 (43) [back to overview]	Number of Participants With Resolution of Abnormal Eye Pigmentation After Discontinuation of Retigabine
NCT01336621 (43) [back to overview]	Number of Participants With Suicidal Ideation or Behavior Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) Score
NCT01336621 (43) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (TESAEs): Safety Population
NCT01336621 (43) [back to overview]	Number of Participants With Urinalysis Parameters of PCC
NCT01336621 (43) [back to overview]	Time From Discontinuation of Retigabine to Resolution of Abnormal Eye Pigmentation
NCT01494584 (26) [back to overview]	Change From Baseline in Mean Corpuscle Volume at Day 7 Post Each Up-titration
NCT01494584 (26) [back to overview]	Change From Baseline in Calcium, Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Sodium, Inorganic Phosphorus, and Urea/Blood Urea Nitrogen (BUN) at Day 7 Post Each Up-titration
NCT01494584 (26) [back to overview]	Change From Baseline in Direct Bilirubin, Total Bilirubin, Creatinine, and Uric Acid at Day 7 Post Each Up-titration
NCT01494584 (26) [back to overview]	Number of Participants With the Indicated Urinalysis Parameter Dipstick Test Results From Screening to Follow-up
NCT01494584 (26) [back to overview]	Number of Participants With the Indicated Neurological Abnormality
NCT01494584 (26) [back to overview]	Number of Participants With Abnormal Electrocardiogram (ECG) Findings
NCT01494584 (26) [back to overview]	Maximum Observed Concentration (Cmax) and Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) Following Oral Administration of Ezogabine/Retigabine
NCT01494584 (26) [back to overview]	Change From Baseline in Heart Rate (HR)
NCT01494584 (26) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points
NCT01494584 (26) [back to overview]	Apparent Clearance (CL/F) Following Oral Administration of Ezogabine/Retigabine
NCT01494584 (26) [back to overview]	Apparent Volume of Distribution (Vd/F) Following Oral Administration of Ezogabine/Retigabine
NCT01494584 (26) [back to overview]	Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t]) for the N-acetyl Metabolite of Ezogabine/Retigabine
NCT01494584 (26) [back to overview]	Change From Baseline in Hematocrit at Day 7 Post Each Up-titration
NCT01494584 (26) [back to overview]	Change From Baseline in Mean Corpuscle Hemoglobin at Day 7 Post Each Up-titration
NCT01494584 (26) [back to overview]	Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration at Day 7 Post Each Up-titration
NCT01494584 (26) [back to overview]	Change From Baseline in Post Void Residual Ultrasound at Day 21
NCT01494584 (26) [back to overview]	Change From Baseline in Red Blood Cell Count at Day 7 Post Each Up-titration
NCT01494584 (26) [back to overview]	Number of Participants With Any Adverse Event (AE)
NCT01494584 (26) [back to overview]	Percent Change From Baseline in 28-day Seizure Frequency Rate
NCT01494584 (26) [back to overview]	Plasma Half Life at Steady State (t1/2) Following Oral Administration of Ezogabine/Retigabine
NCT01494584 (26) [back to overview]	Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) for the N-acetyl Metabolite of Ezogabine/Retigabine
NCT01494584 (26) [back to overview]	The Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) Following Oral Administration of Ezogabine/Retigabine
NCT01494584 (26) [back to overview]	Time to Maximum Concentration (Tmax) Following Oral Administration of Ezogabine/Retigabine
NCT01494584 (26) [back to overview]	Change From Baseline in Albumin and Total Protein at Day 7 Post Each Up-titration
NCT01494584 (26) [back to overview]	Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, and Gamma Glutamyl Transferase at Day 7 Post Each Up-titration
NCT01494584 (26) [back to overview]	Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Total ANC [Total Absolute Neutrophil Count]), Platelet Count, and White Blood Cell Count at Day 7 Post Each Up-titration
NCT01607346 (12) [back to overview]	Change From Baseline in Maximum Flow Rate (Qmax) at Visit 5.
NCT01607346 (12) [back to overview]	Frequency of Micturition as Recorded on the Voiding Diary for 2 Days Prior to Each Visit
NCT01607346 (12) [back to overview]	Percent Change From Baseline in Qmax at Visits 3, 4, 5 and 6
NCT01607346 (12) [back to overview]	Volume Voided as Recorded on the Voiding Diary for 2 Days Prior to Each Post-baseline Visit
NCT01607346 (12) [back to overview]	Change From Baseline in Flow Time at Visits 3, 4, 5 and 6
NCT01607346 (12) [back to overview]	Change From Baseline in American Urological Association Symptom Index (AUA SI) at Visits 3, 4, 5 and 6
NCT01607346 (12) [back to overview]	Change From Baseline in Average Flow Rate (Qmean) at Visits 3, 4, 5 and 6
NCT01607346 (12) [back to overview]	Change From Baseline in Maximum Flow Rate (Qmax) at Visits 3, 4 and 6
NCT01607346 (12) [back to overview]	Change From Baseline in Percentage Residual Urinary Volume (RUV) at Visits 3, 4, 5 and 6
NCT01607346 (12) [back to overview]	Change From Baseline in PVR Volume by Bladder Ultrasound at Visits 3, 4, 5 and 6
NCT01607346 (12) [back to overview]	Change From Baseline in Time to Maximum Flow at Visits 3, 4, 5 and 6
NCT01607346 (12) [back to overview]	Change From Baseline in Voided Volume (VV) at Visits 3, 4, 5 and 6
NCT01648101 (10) [back to overview]	Number of Participants Who Were Seizure Free During the MP, ITT Population
NCT01648101 (10) [back to overview]	Percentage of Seizure-free Days in the TrP
NCT01648101 (10) [back to overview]	Number of Placebo and Retigabine 600 mg Responders During the MP
NCT01648101 (10) [back to overview]	Number of Placebo and Retigabine 900 mg Responders During the Maintenance Phase (MP)
NCT01648101 (10) [back to overview]	Percentage of Seizure-free Days in the MP
NCT01648101 (10) [back to overview]	Number of Responders From the BP to the Treatment Phase (TrP)
NCT01648101 (10) [back to overview]	Percent Change From Baseline in the 28-day Total POS Frequency During the TrP
NCT01648101 (10) [back to overview]	Percent Change From Baseline in the 28-day Total POS Frequency During the MP
NCT01648101 (10) [back to overview]	Incidence of New Seizure Types During the TrP in Participants Without a History of the Indicated Seizure Types at Baseline
NCT01648101 (10) [back to overview]	Number of Participants Who Were Seizure Free During the TrP
NCT01668654 (6) [back to overview]	Number of Participants With Sexual Maturation Based on the Tanner Stage I to Stage V of Puberty in Participants <=18 Years Old Throughout the Study
NCT01668654 (6) [back to overview]	Number of Days of Exposure to Retigabine/Ezogabine TID by Individual Participant
NCT01668654 (6) [back to overview]	Number of Participants With Vital Signs Outside the Pre-determined Clinically Important Findings or Outside the Normal Ranges at Any Time During the Study
NCT01668654 (6) [back to overview]	Number of Participants With Abnormal Clinically Significant ECG Findings Based on Investigator Judgment at Anytime During the Study
NCT01668654 (6) [back to overview]	Number of Participants With AEs Leading to Withdrawal
NCT01668654 (6) [back to overview]	Number of Participants (Par.) With Any Adverse Event (AE) or Serious Adverse Event (SAE) During the Treatment Period
NCT01721317 (2) [back to overview]	Number of Participants With the Indicated Assessment Events of Suicidal Behavior, Suicidal Ideation or Non-suicidal Self Injurious Behavior Via the Columbia Suicide Severity Rating Scale (C-SSRS)
NCT01721317 (2) [back to overview]	Number of Participants With Early Study Discontinuation
NCT01777139 (35) [back to overview]	Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (Alk. Phosph.), Aspartate Aminotransferase (AST), Creatine Kinase (CK), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD)
NCT01777139 (35) [back to overview]	Change From Baseline in Albumin and Total Protein
NCT01777139 (35) [back to overview]	Number of Participants Who Discontinued From RTG
NCT01777139 (35) [back to overview]	Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils, and White Blood Cell Count (WBC)
NCT01777139 (35) [back to overview]	Change From Baseline in Blood Urea Nitrogen (BUN)/Creatinine Ratio
NCT01777139 (35) [back to overview]	Change From Baseline in Calcium, Carbon Dioxide (CO2) Content/Bicarbonate (Bicarb), Chloride, Glucose, Magnesium, Potassium, Sodium, Urea/BUN
NCT01777139 (35) [back to overview]	Change From Baseline in Creatinine, Direct Bilirubin, Total Bilirubin, and Uric Acid
NCT01777139 (35) [back to overview]	Change From Baseline in Hematocrit
NCT01777139 (35) [back to overview]	Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC)
NCT01777139 (35) [back to overview]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Level
NCT01777139 (35) [back to overview]	Change From Baseline in Mean Corpuscle Volume (MCV) and Mean Platelet Volume (MPV)
NCT01777139 (35) [back to overview]	Change From Baseline in Post-void Residual (PVR) Bladder Ultrasound Volumes
NCT01777139 (35) [back to overview]	Change From Baseline in Red Blood Cell (RBC) Count
NCT01777139 (35) [back to overview]	Change From Baseline in Red Cell Distribution Width (RDW)
NCT01777139 (35) [back to overview]	Change From Baseline in Urine Albumin/Creatinine Ratio
NCT01777139 (35) [back to overview]	Change From Baseline in Urine Creatinine Concentration
NCT01777139 (35) [back to overview]	Number of Participants With Abnormal Urinalysis Values (Categorical Data)
NCT01777139 (35) [back to overview]	Number of Participants With PCC Values of Change From Baseline for Body Weight
NCT01777139 (35) [back to overview]	Number of Participants With PCC Values of Change From Baseline for Electrocardiogram (ECG) Parameters
NCT01777139 (35) [back to overview]	Number of Participants With Potential Clinical Concern (PCC) Values of Change From Baseline for Vital Signs
NCT01777139 (35) [back to overview]	Number of Participants With Resolution of Abnormal Eye Pigmentation After Discontinuation of RTG
NCT01777139 (35) [back to overview]	Number of Participants With Suicidal Ideation or Behavior During Treatment Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT01777139 (35) [back to overview]	Number of Participants With Treatment Emergent (TE) Serious Adverse Events (SAEs) and Non-SAEs
NCT01777139 (35) [back to overview]	Potential of Hydrogen (pH) of Urine at Indicated Time Points
NCT01777139 (35) [back to overview]	Specific Gravity of Urine at Indicated Time Points
NCT01777139 (35) [back to overview]	Change From Baseline in American Urological Association (AUA) Symptom Scale Scores
NCT01777139 (35) [back to overview]	Number of Participants With Resolution of Dermatologist-confirmed Abnormal Discoloration After Discontinuation of RTG
NCT01777139 (35) [back to overview]	Percent Change From Baseline in 28-day Total POS Frequency
NCT01777139 (35) [back to overview]	Percentage of Participants With a Clinically Significant Decrease in Visual Acuity From Initial Examination
NCT01777139 (35) [back to overview]	Percentage of Participants With Decrease in Confrontational Visual Field From Initial Examination
NCT01777139 (35) [back to overview]	Percentage of Participants With Dermatologist-confirmed Abnormal Discoloration
NCT01777139 (35) [back to overview]	Percentage of Participants With Pigmentation of Non-retinal Ocular Tissues
NCT01777139 (35) [back to overview]	Percentage of Participants With Retinal Pigmentary Abnormalities
NCT01777139 (35) [back to overview]	Percentage of Participants With TEAEs Leading to Study Discontinuation
NCT01777139 (35) [back to overview]	Percentage of Responders to POS Frequency
NCT02149836 (4) [back to overview]	Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT02149836 (4) [back to overview]	Patient Rated Inventory of Side Effects (PRISE)
NCT02149836 (4) [back to overview]	Changes in Reward System Activation After Treatment With Ezogabine
NCT02149836 (4) [back to overview]	Montgomery-Asberg Depression Rating Scale Comparison to Baseline
NCT02450552 (12) [back to overview]	Number of Participants Who Tolerate Study Drug
NCT02450552 (12) [back to overview]	Hand Held Dynamometry Force Measurement for Abductor Pollicis Brevis
NCT02450552 (12) [back to overview]	Proportion of Days With Fasciculations
NCT02450552 (12) [back to overview]	Muscle Cramping Frequency
NCT02450552 (12) [back to overview]	Change in Strength Duration Time Constant
NCT02450552 (12) [back to overview]	Change in Short-interval Intracortical Inhibition (SICI) Measured by Transcranial Magnetic Stimulation (TMS)
NCT02450552 (12) [back to overview]	Change in Resting Motor Evoked Potential (MEP) Threshold (Prespecified Secondary Outcome of Primary Importance)
NCT02450552 (12) [back to overview]	Change in Recovery Cycle
NCT02450552 (12) [back to overview]	Change in MEP Amplitude
NCT02450552 (12) [back to overview]	Change in Intracortical Facilitation
NCT02450552 (12) [back to overview]	Change in Duration of Cortical Silent Period
NCT02450552 (12) [back to overview]	Change in Electrotonus
NCT03043560 (9) [back to overview]	Clinical Global Impression - Severity (CGI-S)
NCT03043560 (9) [back to overview]	Montgomery-Asberg Depression Rating Scale (MADRS)
NCT03043560 (9) [back to overview]	Specific Loss of Interest and Pleasure Scale (SLIPS)
NCT03043560 (9) [back to overview]	Temporal Experience of Pleasure Scale (TEPS)
NCT03043560 (9) [back to overview]	World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
NCT03043560 (9) [back to overview]	Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)
NCT03043560 (9) [back to overview]	Change in Snaith-Hamilton Pleasure Scale (SHAPS)
NCT03043560 (9) [back to overview]	Change in Ventral Striatum (VS) Activation
NCT03043560 (9) [back to overview]	Clinical Global Impression - Improvement (CGI-I)

Number of Participants Reporting New Seizure Types in the Indicated Categories During the DB Phase (Titration and Maintenance Phases) That Were Not Reported at Baseline

New seizure types included those seizures which were not reported by any participant at Baseline. (NCT00232596)
Timeframe: Baseline (Week -7 through Week 0), Week 1 through Week 18

Intervention	participants (Number)
	No new seizure type	Partial seizures without motor signs	Partial evolving to secondarily generalized	Complex partial seizures	Partial seizures with motor signs	Flurries	Tonic-clonic seizures	Atonic seizures
Placebo - DB Phase (Titration + Maintenance)	33	12	7	5	11	3	0	1
Retigabine DB Phase (Titration + Maintenance)	42	17	12	11	7	1	1	0

Intervention	participants (Number)
	75% to 100% reduction	50% to <75% reduction	25% to <50% reduction	>0 to <25% reduction	No reduction
Placebo - DB Phase (Titration + Maintenance)	6	21	37	33	55
Retigabine DB Phase (Titration + Maintenance)	27	41	20	26	39

Intervention	participants (Number)
	0% to 25% increase	>=25% increase	>0% reduction
Placebo - Maintenance Phase	20	21	96
Retigabine - Maintenance Phase	4	16	99

Intervention	participants (Number)
	Urinary hesitation	Dysuria	Chromaturia	Polyuria	Nephrolithiasis	Hematuria	Urinary retention
Placebo - DB Phase (Titration and Maintenance)	1	2	0	1	0	1	2
Placebo (DB Phase) and Retigabine (Transition Phase)	2	2	0	0	0	2	2
Retigabine - DB Phase (Titration and Maintenance)	9	8	7	4	4	2	1
Retigabine (DB Phase) and Retigabine (Transition Phase)	0	1	0	0	0	0	0

Intervention	participants (Number)
	Responders	Non-responders
Placebo - DB Phase (Titration + Maintenance)	27	125
Retigabine - DB Phase (Titration + Maintenance)	68	85

Intervention	participants (Number)
	Seizure free	Not seizure free
Placebo - DB Phase (Titration + Maintenance)	0	150
Retigabine DB Phase (Titration + Maintenance)	3	148

Intervention	participants (Number)
	Urine analysis abnormal	Bacteria urine	Hematology test abnormal	Urinary sediment present
Placebo - DB Phase (Titration and Maintenance)	3	1	0	1
Placebo (DB Phase) and Retigabine (Transition Phase)	3	0	0	0
Retigabine - DB Phase (Titration and Maintenance)	4	1	1	0
Retigabine (DB Phase) and Retigabine (Transition Phase)	2	2	2	2

Intervention	participants (Number)
	Titration Phase, Week 2, n=149, 150	Titration Phase, Week 4, n=145, 144	Titration Phase, Week 6, n=146, 129	Maintenance Phase, Week 7, n=130, 121	Maintenance Phase, Week 8, n=135, 128	Maintenance Phase, Week 10, n=136, 119	Maintenance Phase, Week 14, n=137, 109	Maintenance Phase, Week 18, n=127, 92
Placebo - DB Phase (Titration + Maintenance)	0	0	1	2	1	3	3	4
Retigabine DB Phase (Titration + Maintenance)	5	5	6	9	10	15	18	17

Intervention	participants (Number)
	Reduction: 90% to 100%	Reduction: 80% to <90%	Reduction: 70% to <80%	Reduction: 60% to <70%	Reduction: 50% to <60%	Reduction: 40% to <50%	Reduction: 30% to <40%	Reduction: 20% to <30%	Reduction: 10% to <20%	Reduction: >0% to <10%	Increase: 0% to 10%	Increase: >10% to 20%	Increase: >20% to 30%	Increase: >30%
Placebo - DB Phase (Titration + Maintenance)	0	5	4	7	11	11	13	19	13	14	14	12	4	25
Retigabine DB Phase (Titration + Maintenance)	12	11	10	20	15	10	6	12	10	8	10	5	4	20

Intervention	participants (Number)
	>75% reduction	50% to 75% reduction	>0 to <50% reduction	No reduction
Placebo - Maintenance Phase	13	18	65	41
Retigabine - Maintenance Phase	37	29	33	20

Intervention	scores on a scale (Mean)
	Baseline (Week -7 through Week 0), n=139, 137	Week 6 (Titration Phase), n=127, 108	Week 10 (Maintenance Phase), n=121, 102	Week 18 (Maintenance Phase), n=116, 85
Placebo - DB Phase (Titration + Maintenance)	52.6	55.2	57.9	57.3
Retigabine DB Phase (Titration + Maintenance)	55.6	55.7	56.2	53.8

Intervention	percent change in seizure frequency (Median)
Placebo - Maintenance Phase	-18.9
Retigabine - Maintenance Phase	-54.5

Intervention	percent change in seizure frequency (Median)
Placebo - DB Phase (Titration + Maintenance)	-17.5
Retigabine - DB Phase (Titration + Maintenance)	-44.3

Intervention	percentage of days (Median)
Placebo - DB Phase (Titration + Maintenance)	77.3
Retigabine DB Phase (Titration + Maintenance)	84.1

Intervention	percentage of days (Median)
Placebo - Maintenance Phase	78.2
Retigabine - Maintenance Phase	86.9

Intervention	milliliters (Median)
	Week 10, n=111, 100	Week 18, n=95, 76
Placebo - DB Phase (Titration and Maintenance)	-1.0	-3.0
Retigabine - DB Phase (Titration and Maintenance)	0.0	0.0

Intervention	participants (Number)
	Responders	Non-responders
Placebo - DB Phase (Titration Plus Maintenance)	31	148
Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)	57	124
Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)	70	108

Intervention	participants (Number)
	Seizure-free	Not seizure-free
Placebo - DB Phase (Titration Plus Maintenance)	2	174
Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)	0	179
Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)	7	168

Intervention	participants (Number)
	Protenuria	Hyperlipidemia	Hypercholesterolemia	Hematuria
Placebo - DB Phase (Titration Plus Maintenance)	3	3	2	2
Placebo - Transition Phase	0	0	0	1
Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)	2	0	4	5
Retigabine 200 mg TID - Transition Phase	1	0	0	0
Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)	0	0	1	2
Retigabine 300 mg TID - Transition Phase	0	0	1	1

Intervention	participants (Number)
	Week 2, n=174, 180, 175	Week 4, n=169, 172, 167	Week 6, n=169, 165, 152	Week 8, n=161, 160, 149	Week 12, n=159, 151, 144	Week 16, n=153, 139, 132
Placebo - DB Phase (Titration Plus Maintenance)	0	0	1	1	6	4
Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)	3	7	8	9	15	13
Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)	3	8	7	7	13	12

Intervention	scores on a scale (Mean)
	Baseline, n=165, 173, 166	Week 4 (Titration Phase), n=155, 155, 149)	Week 8 (Maintenance Phase), n=141, 146, 127	Week 16 (Maintenance Phase), n=143, 133, 123
Placebo - DB Phase (Titration Plus Maintenance)	53.3	55.4	55.3	54.7
Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)	56.0	57.3	59.6	59.1
Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)	52.1	52.7	52.7	53.2

ezogabine

Description

Cross-References

Synonyms (94)

Research Excerpts

Overview

Effects

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Occurs in Manufacturing (1 Product(s))

Product Categories

Products

Roles (2)

Drug Classes (4)

Protein Targets (35)

Potency Measurements

Activation Measurements

Other Measurements

Biological Processes (106)

Molecular Functions (32)

Ceullar Components (36)

Bioassays (203)

Research

Studies (375)

Market Indicators

Research Demand Index: 39.93

Study Types

Clinical Trials (25)

Trial Overview

Trial Outcomes

Number of Participants Reporting New Seizure Types in the Indicated Categories During the DB Phase (Titration and Maintenance Phases) That Were Not Reported at Baseline

Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories

Number of Participants Who Experienced the Indicated Level of Exacerbation and Reduction in the 28-day Total Partial Seizure Frequency From Baseline During the Maintenance Phase

Number of Participants Who Reported the Indicated Renal and Urinary Disorder Adverse Events at a Frequency Threshold of 2% (in Any Treatment Arm)

Number of Participants Who Were Responders and Non-responders in the DB Phase

Number of Participants Who Were Responders and Non-responders in the Maintenance Phase

Number of Participants Who Were Seizure-free During the DB Phase (Titration and Maintenance Phases)

Number of Participants Who Were Seizure-free During the Maintenance Phase

Number of Participants Whose Clinical Laboratory Values Were Deemed an Adverse Event by the Investigator (>=2% in Any Treatment Arm)

Number of Participants With a >=7% Increase in Body Weight During Weeks 2, 4, and 6 of theTitration Phase and Weeks 7, 8, 10, 14, and 18 of the Maintenance Phase

Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of the DB Phase (Titration and Maintenance Phases) by Indicated Decile Reduction and Increase Categories

Number of Participants With the Indicated Reduction From Baseline in the 28-day Total Partial Seizure Frequency During the Maintenance Phase

Quality of Life (QOL) Assessed by QOL in Epilepsy-Problems Questionnaire (QOLIE-31-P) at Baseline (Week 0) and Weeks 6, 10, and 18

Clinical Global Impression-Improvement (CGI-I) Score at the End of the Maintenance Phase

Patient Global Impression (PGI) Score at the End of the Maintenance Phase

Percent Change From Baseline (BL) in the 28-day Total Partial Seizure Frequency During the Maintenance Phase

Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)

Percentage of Seizure-free Days During the DB Phase (Titration and Maintenance Phases)

Percentage of Seizure-free Days During the Maintenance Phase

Change From Baseline in Post-void Residual Urine Volume at Weeks 10 and 18 of the DB Treatment Phase

Number of Participants Who Were Responders and Non-responders During the DB Phase

Number of Participants Who Were Seizure-free During the DB Phase (Titration and Maintenance Phases)

Number of Participants Who Were Seizure-free During the Maintenance Phase

Number of Participants Whose Clinical Laboratory Values Were Deemed an Adverse Event by the Investigator (>=2% in Any Treatment Arm)

Number of Participants With a >=7% Increase in Body Weight During Weeks 2 and 4 of theTitration Phase and Weeks 6, 8, 12, and 16 of the Maintenance Phase

Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the DB Phase (Titration and Maintenance Phases) by Indicated Decile Reduction and Increase Categories

Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories

Number of Participants With the Indicated Reduction From Baseline in the 28-day Total Partial Seizure Frequency During the Maintenance Phase

Quality of Life Assessed by Quality of Life in Epilepsy-Problems Questionnaire (QOLIE-31-P) at BL (Week 0) and Weeks 4, 8, and 16

Patient Global Impression (PGI) Score at the End of the Maintenance Phase

Percent Change From Baseline (BL) in the 28-day Total Partial Seizure Frequency During the Maintenance Phase

Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)

Percentage of Seizure-free Days During the DB Phase (Titration and Maintenance Phases)

Percentage of Seizure-free Days During the Maintenance Phase

Change From Baseline in Post-void Residual Urine Volume at Weeks 8 and 16 of the Maintenance Phase

Number of Participants Classified as Responders and Non-responders During the Maintenance Phase

Number of Participants Reporting New Seizure Types in the Indicated Categories During the DB Phase (Titration and Maintenance Phases) That Were Not Reported at Baseline

Number of Participants Who Experienced the Indicated Level of Exacerbation and Reduction in the 28-day Total Partial Seizure Frequency From Baseline During the Maintenance Phase

Clinical Global Impression-Improvement (CGI-I) Score at the End of the Maintenance Phase

Number of Participants Who Reported the Indicated Renal and Urinary Disorder Adverse Events at a Frequency Threshold of 2% (in Any Treatment Arm)

Number of Participants Who Were Seizure Free for Any 12 Continuous Months

Number of Participants Who Were Seizure Free for Any 6 Continuous Months

Number of Participants With a Decrease in Confrontational Visual Field From Initial Examination

Number of Participants With Pigmentation of Non-retinal Ocular Tissue

Number of Participants With Pigmentation of Retinal Ocular Tissue

Number of Participants With Resolution of Dermatologist Confirmed Abnormal Discoloration After Discontinuation of Retigabine

Number of Participants With Treatment-emergent Adverse Events Leading to Withdrawal From Study Drug

Number of Responders

Intervention	Percent change in seizure frequency (Median)
Placebo - DB Phase (Titration Plus Maintenance)	-17.4
Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)	-35.3
Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)	-44.3

Intervention	percent change in seizure frequency (Median)
Placebo - Double Blind (DB) Phase (Titration Plus Maintenance)	-15.9
Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)	-39.9
Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)	-27.9

Intervention	percentage of days (Median)
Placebo - DB Phase (Titration Plus Maintenance)	77.8
Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)	79.5
Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)	82.1

Intervention	percentage of days (Median)
Placebo - DB Phase (Titration Plus Maintenance)	78.1
Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)	81.6
Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)	84.5

Intervention	milliliters (Median)
	Week 8, n=143, 134, 121	Week 16, n=141, 131, 115
Placebo: Maintenance Phase	0	0
Retigabine 200 mg TID: Maintenance Phase	0	0
Retigabine 300 mg TID: Maintenance Phase	0	0

Intervention	Beats per Minute (Mean)
	Su HR Mon 1, n=174	Su HR Mon 3, n=159	Su HR Mon 6, n=143	Su HR Mon 9, n=124	Su HR Mon 12, n=173	Su HR Mon 16, n=104	Su HR Mon 20, n=100	Su HR Mon 24, n=112	Su HR Mon 28, n=88	Su HR Mon 32, n=85	Su HR Mon 36, n=92	Su HR Mon 40, n=78	Su HR Mon 44, n=76	Su HR Mon 48, n=82	Su HR Mon 52, n=67	Su HR Mon 56, n=63	Su HR Mon 60, n=70	Su HR Mon 64, n=50	Su HR Mon 68, n=45	Su HR Mon 72, n=57	Su HR Mon 76, n=31	Su HR Mon 80, n=24	Su HR Mon 84, n=36	Su HR Mon 88, n=17	Su HR Mon 92, n=16	Su HR Mon 96, n=19	Su HR Mon 100, n=7	Su HR Mon 104, n=1	Su HR Mon 108, n=10	St HR Mon 1, n=174	St HR Mon 3, n=158	St HR Mon 6, n=143	St HR Mon 9, n=124	St HR Mon 12, n=170	St HR Mon 16, n=104	St HR Mon 20, n=100	St HR Mon 24, n=110	St HR Mon 28, n=87	St HR Mon 32, n=84	St HR Mon 36, n=91	St HR Mon 40, n=77	St HR Mon 44, n=75	St HR Mon 48, n=81	St HR Mon 52, n=67	St HR Mon 56, n=62	St HR Mon 60, n=69	St HR Mon 64, n=49	St HR Mon 68, n=45	St HR Mon 72, n=56	St HR Mon 76, n=30	St HR Mon 80, n=23	St HR Mon 84, n=35	St HR Mon 88, n=17	St HR Mon 92, n=16	St HR Mon 96, n=19	St HR Mon 100, n=7	St HR Mon 104, n=1	St HR Mon 108, n=10
Overall Study	-1.0	-0.7	-0.2	-1.0	-0.1	1.1	1.1	-0.1	-0.8	0.4	-1.7	-0.6	-2.8	-2.1	-1.5	-1.8	-1.2	-2.1	1.2	-1.9	-1.6	-2.2	-2.4	1.5	-2.7	-1.0	-8.3	-6.0	-3.4	0.7	1.0	1.6	1.1	2.3	2.5	0.2	2.6	-0.8	1.7	-0.4	0.4	-0.3	-1.9	-0.3	1.3	-0.2	1.3	4.1	0.4	1.9	3.0	0.2	3.6	3.1	3.2	2.6	0.0	-5.4

Intervention	10^12 cells/Liter(L) (Mean)
	RBC, Mon 1, n=169	RBC, Mon 2, n=15	RBC, Mon 3, n=154	RBC, Mon 4, n=26	RBC, Mon 6, n=137	RBC, Mon 8, n=43	RBC, Mon 9, n=122	RBC, Mon 10, n=55	RBC, Mon 12, n=167	RBC, Mon 16, n=99	RBC, Mon 20, n=96	RBC, Mon 24, n=110	RBC, Mon 28, n=85	RBC, Mon 32, n=86	RBC, Mon 36, n=91	RBC, Mon 40, n=78	RBC, Mon 44, n=74	RBC, Mon 48, n=79	RBC, Mon 52, n=68	RBC, Mon 56, n=63	RBC, Mon 60, n=71	RBC, Mon 64, n=49	RBC, Mon 68, n=44	RBC, Mon 72, n=53	RBC, Mon 76, n=31	RBC, Mon 80, n=24	RBC, Mon 84, n=35	RBC, Mon 88, n=16	RBC, Mon 92, n=15	RBC, Mon 96, n=19	RBC, Mon 100, n=7	RBC, Mon 104, n=1	RBC, Mon 108, n=10
Overall Study Arm	-0.09	0.01	-0.06	-0.16	-0.04	-0.03	-0.06	-0.01	0.00	-0.04	0.01	-0.01	-0.04	-0.03	-0.11	-0.11	-0.09	-0.16	-0.08	-0.13	-0.14	-0.10	-0.06	-0.09	0.00	-0.03	-0.00	0.03	0.14	0.04	0.23	0.30	0.15

Intervention	10^9 cells/Liter (Mean)
	Bands, Mon 1, n=2	Bands, Mon 9, n=2	Bands, Mon 20, n=2	Basophils, Mon 1, n=168	Basophils, Mon 2, n=15	Basophils, Mon 3, n=153	Basophils, Mon 4, n=26	Basophils, Mon 6, n=137	Basophils, Mon 8, n=42	Basophils, Mon 9, n=121	Basophils, Mon 10, n=54	Basophils, Mon 12, n=165	Basophils, Mon 16, n=96	Basophils, Mon 20, n=92	Basophils, Mon 24, n=109	Basophils, Mon 28, n=84	Basophils, Mon 32, n=81	Basophils, Mon 36, n=91	Basophils, Mon 40, n=74	Basophils, Mon 44, n=72	Basophils, Mon 48, n=77	Basophils, Mon 52, n=65	Basophils, Mon 56, n=63	Basophils, Mon 60, n=71	Basophils, Mon 64, n=49	Basophils, Mon 68, n=43	Basophils, Mon 72, n=53	Basophils, Mon 76, n=31	Basophils, Mon 80, n=24	Basophils, Mon 84, n=33	Basophils, Mon 88, n=16	Basophils, Mon 92, n=15	Basophils, Mon 96, n=19	Basophils, Mon 100, n=7	Basophils, Mon 104, n=1	Basophils, Mon 108, n=10	Eosinophils, Mon 1, n=168	Eosinophils, Mon 2, n=15	Eosinophils, Mon 3, n=153	Eosinophils, Mon 4, n=26	Eosinophils, Mon 6, n=137	Eosinophils, Mon 8, n=42	Eosinophils, Mon 9, n=121	Eosinophils, Mon 10, n=54	Eosinophils, Mon 12, n=165	Eosinophils, Mon 16, n=96	Eosinophils, Mon 20, n=92	Eosinophils, Mon 24, n=109	Eosinophils, Mon 28, n=84	Eosinophils, Mon 32, n=81	Eosinophils, Mon 36, n=91	Eosinophils, Mon 40, n=74	Eosinophils, Mon 44, n=72	Eosinophils, Mon 48, n=77	Eosinophils, Mon 52, n=65	Eosinophils, Mon 56, n=63	Eosinophils, Mon 60, n=71	Eosinophils, Mon 64, n=49	Eosinophils, Mon 68, n=43	Eosinophils, Mon 72, n=53	Eosinophils, Mon 76, n=31	Eosinophils, Mon 80, n=24	Eosinophils, Mon 84, n=33	Eosinophils, Mon 88, n=16	Eosinophils, Mon 92, n=15	Eosinophils, Mon 96, n=19	Eosinophils, Mon 100, n=7	Eosinophils, Mon 104, n=1	Eosinophils, Mon 108, n=10	Lymphocytes, Mon 1, n=168	Lymphocytes, Mon 2, n=15	Lymphocytes, Mon 3, n=153	Lymphocytes, Mon 4, n=26	Lymphocytes, Mon 6, n=137	Lymphocytes, Mon 8, n=42	Lymphocytes, Mon 9, n=121	Lymphocytes, Mon 10, n=54	Lymphocytes, Mon 12, n=165	Lymphocytes, Mon 16, n=96	Lymphocytes, Mon 20, n=92	Lymphocytes, Mon 24, n=109	Lymphocytes, Mon 28, n=84	Lymphocytes, Mon 32, n=81	Lymphocytes, Mon 36, n=91	Lymphocytes, Mon 40, n=74	Lymphocytes, Mon 44, n=72	Lymphocytes, Mon 48, n=77	Lymphocytes, Mon 52, n=65	Lymphocytes, Mon 56, n=63	Lymphocytes, Mon 60, n=71	Lymphocytes, Mon 64, n=49	Lymphocytes, Mon 68, n=43	Lymphocytes, Mon 72, n=53	Lymphocytes, Mon 76, n=31	Lymphocytes, Mon 80, n=24	Lymphocytes, Mon 84, n=33	Lymphocytes, Mon 88, n=16	Lymphocytes, Mon 92, n=15	Lymphocytes, Mon 96, n=19	Lymphocytes, Mon 100, n=7	Lymphocytes, Mon 104, n=1	Lymphocytes, Mon 108, n=10	Metamyelocyte, Mon 3, n=1	Monocytes, Mon 1, n=168	Monocytes, Mon 2, n=15	Monocytes, Mon 3, n=153	Monocytes, Mon 4, n=26	Monocytes, Mon 6, n=137	Monocytes, Mon 8, n=42	Monocytes, Mon 9, n=121	Monocytes, Mon 10, n=54	Monocytes, Mon 12, n=165	Monocytes, Mon 16, n=96	Monocytes, Mon 20, n=92	Monocytes, Mon 24, n=109	Monocytes, Mon 28, n=84	Monocytes, Mon 32, n=81	Monocytes, Mon 36, n=91	Monocytes, Mon 40, n=74	Monocytes, Mon 44, n=72	Monocytes, Mon 48, n=77	Monocytes, Mon 52, n=65	Monocytes, Mon 56, n=63	Monocytes, Mon 60, n=71	Monocytes, Mon 64, n=49	Monocytes, Mon 68, n=43	Monocytes, Mon 72, n=53	Monocytes, Mon 76, n=31	Monocytes, Mon 80, n=24	Monocytes, Mon 84, n=33	Monocytes, Mon 88, n=16	Monocytes, Mon 92, n=15	Monocytes, Mon 96, n=19	Monocytes, Mon 100, n=7	Monocytes, Mon 104, n=1	Monocytes, Mon 108, n=10	Neutrophils, Mon 1, n=168	Neutrophils, Mon 2, n=15	Neutrophils, Mon 3, n=153	Neutrophils, Mon 4, n=26	Neutrophils, Mon 6, n=137	Neutrophils, Mon 8, n=42	Neutrophils, Mon 9, n=121	Neutrophils, Mon 10, n=54	Neutrophils, Mon 12, n=165	Neutrophils, Mon 16, n=96	Neutrophils, Mon 20, n=92	Neutrophils, Mon 24, n=109	Neutrophils, Mon 28, n=84	Neutrophils, Mon 32, n=81	Neutrophils, Mon 36, n=91	Neutrophils, Mon 40, n=74	Neutrophils, Mon 44, n=72	Neutrophils, Mon 48, n=77	Neutrophils, Mon 56, n=63	Neutrophils, Mon 52, n=65	Neutrophils, Mon 60, n=71	Neutrophils, Mon 64, n=49	Neutrophils, Mon 68, n=43	Neutrophils, Mon 72, n=53	Neutrophils, Mon 76, n=31	Neutrophils, Mon 80, n=24	Neutrophils, Mon 84, n=33	Neutrophils, Mon 88, n=16	Neutrophils, Mon 92, n=15	Neutrophils, Mon 96, n=19	Neutrophils, Mon 100, n=7	Neutrophils, Mon 104, n=1	Neutrophils, Mon 108, n=10	Platelet Count, Mon 1, n=165	Platelet Count, Mon 2, n=15	Platelet Count, Mon 3, n=150	Platelet Count, Mon 4, n=26	Platelet Count, Mon 6, n=131	Platelet Count, Mon 8, n=42	Platelet Count, Mon 9, n=119	Platelet Count, Mon 10, n=54	Platelet Count, Mon 12, n=161	Platelet Count, Mon 16, n=94	Platelet Count, Mon 20, n=91	Platelet Count, Mon 24, n=104	Platelet Count, Mon 28, n=82	Platelet Count, Mon 32, n=82	Platelet Count, Mon 36, n=87	Platelet Count, Mon 40, n=76	Platelet Count, Mon 48, n=77	Platelet Count, Mon 52, n=65	Platelet Count, Mon 56, n=62	Platelet Count, Mon 60, n=68	Platelet Count, Mon 64, n=47	Platelet Count, Mon 68, n=44	Platelet Count, Mon 72, n=52	Platelet Count, Mon 76, n=31	Platelet Count, Mon 80, n=24	Platelet Count, Mon 84, n=35	Platelet Count, Mon 88, n=16	Platelet Count, Mon 92, n=15	Platelet Count, Mon 96, n=19	Platelet Count, Mon 100, n=7	Platelet Count, Mon 104, n=1	Platelet Count, Mon 108, n=10	WBC, Mon 1, n=169	WBC, Mon 2, n=15	WBC, Mon 3, n=154	WBC, Mon 4, n=26	WBC, Mon 6, n=137	WBC, Mon 8, n=43	WBC, Mon 9, n=122	WBC, Mon 10, n=55	WBC, Mon 12, n=167	WBC, Mon 16, n=99	WBC, Mon 20, n=96	WBC, Mon 24, n=110	WBC, Mon 28, n=85	WBC, Mon 32, n=86	WBC, Mon 36, n=91	WBC, Mon 40, n=78	WBC, Mon 44, n=74	WBC, Mon 48, n=79	WBC, Mon 52, n=68	WBC, Mon 56, n=63	WBC, Mon 60, n=71	WBC, Mon 64, n=49	WBC, Mon 68, n=44	WBC, Mon 72, n=53	WBC, Mon 76, n=31	WBC, Mon 80, n=24	WBC, Mon 84, n=35	WBC, Mon 88, n=16	WBC, Mon 92, n=15	WBC, Mon 96, n=19	WBC, Mon 100, n=7	WBC, Mon 104, n=1	WBC, Mon 108, n=10
Overall Study Arm	-0.135	-0.205	-0.095	-0.001	-0.015	0.001	-0.002	0.004	0.002	0.003	0.001	0.001	0.005	0.004	0.008	0.005	0.005	0.006	0.004	0.004	0.004	-0.004	-0.004	-0.003	-0.003	0.001	-0.003	-0.000	-0.001	0.002	0.003	0.005	0.006	0.021	-0.020	0.012	-0.008	0.023	-0.010	-0.003	-0.015	-0.022	-0.010	0.000	-0.019	-0.006	-0.009	-0.002	-0.016	0.001	-0.006	-0.004	-0.014	-0.002	-0.011	-0.002	-0.014	-0.008	-0.000	0.005	-0.003	-0.010	-0.000	0.030	0.006	0.018	0.033	0.030	-0.005	-0.178	-0.043	-0.134	0.054	-0.055	0.168	-0.031	0.120	0.009	-0.053	-0.031	-0.069	-0.077	0.013	-0.055	-0.028	0.008	0.061	-0.049	-0.065	-0.025	-0.011	-0.002	-0.052	0.104	0.149	0.154	0.189	0.405	0.285	0.144	0.000	0.044	-0.010	0.006	0.002	0.016	0.039	-0.001	0.033	-0.002	0.029	-0.007	-0.021	-0.009	-0.004	-0.031	-0.005	-0.039	-0.013	-0.037	-0.036	-0.026	-0.035	-0.013	-0.024	0.003	-0.007	0.038	0.019	0.065	-0.006	0.029	0.035	0.004	0.070	0.064	0.158	-0.500	0.211	-0.003	0.124	-0.427	0.074	0.211	0.309	0.232	0.145	0.221	-0.032	-0.034	-0.054	0.141	0.003	0.197	0.075	0.151	0.203	-0.042	0.304	0.337	0.380	0.495	0.735	0.036	0.275	0.444	0.156	0.270	0.185	-4.1	5.3	-5.4	-2	-7	6	-4.7	2.9	-5.2	-0.2	-1.9	-11.0	-14.4	-23.2	-24.4	-18.0	-16.1	-17.5	-21.3	-22.3	-20.2	-21.0	-15.7	-11.5	-6.3	-4.3	-10.2	-2.9	-7.2	-14.3	-46.0	-22.3	-0.00	-0.53	0.10	0.17	0.06	-0.11	0.05	0.33	0.30	0.20	0.14	0.16	-0.14	0.02	-0.14	0.13	-0.04	0.24	0.09	-0.04	0.18	-0.09	0.27	0.27	0.51	0.65	0.93	0.25	0.73	0.79	0.36	0.30	0.31

Intervention	Scores on a scale (Mean)
	AUA, Mon 1, n=162	AUA, Mon 3, n=151	AUA, Mon 12, n=153	AUA, Mon 24, n=79	AUA, Mon 36, n=81	AUA, Mon 48, n=79	AUA, Mon 60, n=65	AUA, Mon 72, n=49	AUA, Mon 84, n=33	AUA, Mon 96, n=19	AUA, Mon 108, n=10
Overall Study	-0.2	-0.0	0.2	-0.1	0.0	0.5	0.6	0.4	1.0	-1.0	-0.3

Intervention	Milliliter (mL) (Mean)
	PVR, Mon 1, n=152	PVR, Mon 3, n=146	PVR, Mon 12, n=144	PVR, Mon 24, n=75	PVR, Mon 36, n=84	PVR, Mon 48, n=77	PVR, Mon 60, n=65	PVR, Mon 72, n=48	PVR, Mon 84, n=31	PVR, Mon 96, n=19	PVR, Mon 108, n=10
Overall Study	6.5	5.8	-2.8	11.6	13.6	8.8	20.1	17.2	40.0	8.7	17.4